LimbixHealthInc./1.041ProjectSTAND(Self-guidedTreatmentforAdolescentsNavigatingDepression):arandomizedcontrolledtrialProtocolNumber:LMX-0011/24/23Sponsor:LimbixHealthInc.548MarketStPMB91609SanFrancisco,CA94104-5401Investigators:Dr.AarthiPadmanabhan,PIDr.JessicaLake,PIDr.DaniellaFurman,Sub-IDr.ShanaHall,Sub-IDr.ClaudiaAvina,Sub-IVirtualStudyContactNumber:(650)489-6486
LimbixHealthInc./1.0421.PurposeoftheStudyandBackground1.1PurposeoftheStudyTheprimaryaimoftheproposedresearchistoevaluatetheeffectivenessofaself-guided,cognitivebehavioraltherapy(CBT)-basedmobileapp(SparkRx)+assessment-enhancedUsualCare(eUC)comparedtoeUCaloneasaninterventionforadolescentswithsymptomsofdepressionwhoareunderthesupervisionofalicensedhealthcareprovider.Thisaimwillbeaccomplishedbyevaluating:●AstatisticallysignificantdifferenceinPatientHealthQuestionnaire(PHQ-8)scores(p<0.05)betweenSparkRx+eUC(hereafterreferredtoas“SparkRx”)andeUCaloneatpost-interventionasaprimaryoutcome.ThePatientHealthQuestionnaire(PHQ-8)isprovidedinAppendix1.●Secondary/otheroutcomesofinterventionresponse,remission,interventionsafetybasedonparticipantadverseeventsandadversedeviceeffects,anxietysymptoms,andglobalfunctioning,aswellasretentionrates,programadherence,andusabilityratings.1monthfollow-updatawillalsobeevaluated.1.2Background1.2.1AdolescentdepressionisamajorpublichealthconcernDepression,themostcommonmentalhealthdisorderamongadolescentsandyoungadults,isacriticalhealthproblemwithintheUS,ranking4thinglobalburdenofdisease1,2Annualincidenceofamajordepressiveepisodeamongadolescentsis~3.2million,affecting13.3%ofteenagersandincreasingto26%whenincludingmilddepressivesymptoms3.Ratesofadolescentdepressionarerisingsharply,withglobalprevalenceofdepressivesymptomsestimatedtohavedoubledoverthepastfewyears4.Therehasalsobeena56%increaseinadolescentsuicidesinthelastdecade,makingsuicidethe#2causeofdeathamongstteens5-7.Thesealarmingtrendshighlightanurgencytodevelopeffectiveandaccessibletreatmentsforaffectedadolescents4.Adolescentdepressionhasfar-reachingconsequencesincludingimpairmentsinacademicandworkperformanceandsocialandfamilyrelationships,substanceabuse,andexacerbationofotherhealthconditions8-15.Affectedyoutharealsoatahigherriskfordevelopingarangeofothermentalhealthdisorders,aswellasforunemploymentandphysicalhealthproblemsinadulthood16-19.AdolescentdepressionplacessignificanteconomicburdensontheUShealthcaresystem20,withhighermedicalcoststhanthoseforalmostanyothermentalhealthcondition21.Lastly,depressionisapervasivedisorder22,23,withlifetimerecurrenceratesof~70%24,25,anda$210Bsocietalburdenannuallyasawhole,thustargetingthisprobleminadolescence,thetypicaltimeofinitialonset,iscriticalforimprovingfutureoutcomes.Theproposedstudyissignificantasitwilltargetacriticalpublichealthconcern,theurgencyofwhichisnowmagnifiedbyaglobalpandemicandmandatedsocialdistancing26-28,thatimpactsasignificantproportionofthepopulationandispresentlyaleadingcauseofglobaldisabilityinyouth29.1.2.2EffectivecareforadolescentswithsymptomsofdepressionislimitedAdolescentswithsymptomsofdepressionconstitutealargegroupwithsignificantunmetclinicalneeds.Despitehighprevalenceratesofdepressionamongadolescents,veryfewseektreatmentandtheyaremorepronetodiscontinueorrejectpsychotherapy,duetoconcernsoverprivacyand/orstigma30,31.Inaddition,accesstoeffectivementalhealthcareisoftenlimited32-34.Demandformentalhealthprofessionalshasoutstrippedsupply,particularlyinruralareas,aproblemthatispredictedtointensifyoverthenext10years35-38.Waitlistsformentalhealthprovidersareoftenatleast2-6monthslongandrepresentoneofthemostsubstantialbarrierstoreceivingcare39-44.Consequently,60-80%ofadolescentswithdepressiondonotreceiveappropriateortimelytreatment45,46.MandatedsocialdistancingpracticesimplementedduringtheCOVID-19pandemicmagnifiedthealreadysignificantchallenges47,48.Digitalinterventionisasolutionthatisneededimmediately.Primarycarevisitsprovideauniqueopportunitytoidentifyadolescentswithdepressionanddirectthemtowardsappropriatetreatment.PrimarycarephysiciansoftenserveasagatewayformentalhealthtreatmentsasofficialAmericanAcademyofPediatricsguidelinesrecommendannualdepressionscreeningof
LimbixHealthInc./1.043adolescentsinprimarycare49.However,manyprimarycareproviderslackadequatetimeandtrainingtoprovideeffectivepsychotherapy-basedtreatmentandapprovedoptionsforpharmaceuticaltreatmentswithinadolescentpopulationsarelimited,havelimitedeffectiveness50-52andmayposesafetyconcernsinyouth,includingsideeffectsin10-25%ofusers53,54.50%ofadolescentsdeclineantidepressantuseandonlyaboutathirdofyouthadheretoprescribedantidepressanttherapyafterithasbeeninitiatedinapediatricsetting55,56.Thesesignificantbarriershighlightacriticalneedandopportunityfornewandeffectivetreatmentoptionsforadolescentdepressionthatcanbeprescribedbyprimarycareproviders.Anevidence-based,self-guidedpsychotherapydeliveredviaaprescriptionproductandoverseenbyapediatriciancanbeapromisingadjuncttostandardofcarewithfewanticipatedsideeffectsandcanovercomeexistinglimitationsinaccesstomentalhealthcare,adherence,andsafety.1.2.3DigitalInterventionsforSymptomsofDepressioninAdolescentsAccumulatingevidencehighlightstheefficacyofdigitalhealthinterventionsformentalillness,providingcost-effective,convenient,andaccessiblemeansoftreatment57-59.Digitaltreatmentsviamobileapplicationsholdparticularpromiseforadolescentmentalillness,asyouthincreasinglyreporthighlevelsofsmartphoneuse60andenjoyusingnoveltechnologies57.Digitalinterventionscanbecompletedathome,allowingpatientstopracticeimplementationofclinicalrecommendations61andincreasingaccessibilityofon-demandresources.Critically,suchinterventionscanserveasafirstlineofdefensefortreatment,reducing57higheconomiccostsassociatedwithtraditionalin-personpsychotherapiesandwaittimestoaccessclinically-validatedtreatment.Digitalhealthinterventionscanalsobelessstigmatizing,leadingtohigherratesofengagementandself-disclosure62-65.Mobileapplicationsallowfordeliveryofinteractivecontent,informationcollection,self-report,andremotepatientmonitoring,whichcanbeharnessedtopersonalizeandenhancetreatmentandtointerveneappropriately.TherecentCOVID-19globalpandemichasfurtherunderscoredtheurgencyforsafe,accessible,andeffectivedigitalalternativestostandardmentalhealthtreatments66-69.Thisneediscriticalfortheadolescentpopulationwhoareespeciallyvulnerabletodepressionandsuicidalityfollowingenvironmentalstressors,trauma,andsocialisolation28,48,70-74.Cognitive-behavioraltherapy(CBT)iseffectiveinthepreventionandtreatmentofdepressioninchildrenandadolescents75-80andarecommendedformoftreatmentbytheAmericanAcademyofPediatrics81.DigitalformsofCBT75-80,havebeenshowntobeeffectiveinthetreatmentofanxietyanddepressioninyouth82.BehavioralActivation(BA)83-87,acoreCBTskill,seeksto1)increaseengagementwithadaptiveandcontextuallyrelevantactivitiesthatinducefeelingsofmasteryorpleasure,2)advanceanindividual’spersonalgoalsusingacombinationofmotivationalstrategies,reward-seeking,naturalreinforcers,andself-monitoring,and3)reduceharmfulandavoidantbehaviorsthatoftenmanifestduringdepressiveepisodes83,84,86,87.Adolescentsmaybeespeciallyvulnerabletoreward-relateddeficitsduetoimmaturitiesinrewardprocessingneuralsystems88,89,impactingtheirabilitytobothexperiencerewardandovercomeavoidance.BAcanalsobehelpfulintreatingsymptomsthatespeciallyimpactadolescentswithdepression,includingwithdrawalfromsocialactivities,inactivity,andavoidance90.BA-specifictherapyoffersapromisingapproachfortreatingdepressioninadolescents91-93.GiventhatBAisnecessarilyindividuallypaced,self-driven,andself-monitored,itcanbeeasilydelivereddigitally,whichmaybeappealingtodepressedyouthwhohavelimitedaccesstoorinterestintraditionalcare.RecentevidencesuggeststhatbehavioralaspectsofCBTareequallyeffectiveascognitiveapproachesinreducingdepressivesymptomsinyouthandmaymechanisticallydrivesymptomaticreductioninCBT77,80,89,94.AdigitalBAprogramforadolescentswithsymptomsofdepressionrepresentsanexcitingnewdirectionfortreatment82,95,96.Wehypothesizethatthequantityandqualityofbehavioralactivationscompletedbyadolescentsmaymechanisticallyexplainsymptomimprovementinresponsetoadigitalbehavioralactivationfocuseddigitalintervention.LimbixHealthInc./1.04Despitereportedbenefitsandpreliminaryefficacyofdigitalhealthinterventionsinclinicalresearch,therigorofpreviousresearchisproblematicasstudieshavesufferedfromsmallsamplesizesandwidespreadadoptionofandadherencetosuchinterventionsinclinicalpracticeislimited97-99.Treatmentsdevelopedinresearchsettingsareincongruouswiththosedevelopedforcommercialuse,withtheformerlackingengagingcontent
LimbixHealthInc./1.044andaccessibilityandthelatterlackinganadequateevidencebase.Toourknowledge,therearenocommerciallyavailableinterventionsnorprescriptiondigitaltherapeuticsspecifictoadolescentswithsymptomsofdepression.Wehypothesizethatleveragingengagingmobiletechnologieswillenhancetreatmentengagementandadherence,mediatingclinicaleffectiveness,andultimatelyreducingcostsandwaittimesformentalhealthtreatmentforpatients,closingasignificanttreatmentgapinthecareofadolescentswithsymptomsofdepression.2.CriteriaforSubjectSelection2.1NumberofSubjects220SamplesizecalculationisbasedonprimaryoutcomePHQ-8atpost-intervention.SixPHQ-8measurementswillbecollectedfromeachsubject(baselineandweeklyduringthe5-weekinterventionperiod).Usingatwo-samplet-testapproach,assumingatwo-tailedalphasetat0.05,atotalof200participants(100ineachstudyarm)willgiveus80%powertodetectamoderateeffectsizeofatleastd=0.4.Givenananticipated10%rateofattrition,weaimtoenroll220totalparticipantsinthestudy.2.2SexofSubjectsA50%femalesamplewillbetargeted.Earlierrecruitmenteffortswithinthestudydemographichaveresultedinmajorityfemalesamples,consistentwithprevalencerateswithinthestudypopulation.Assuch,recruitmenteffortswillbeundertakentoensurerepresentationofmaleparticipants.2.3AgeofSubjects13-21yearsold.Adolescentdepressionisontherise,whichcanhavedeleteriouseffectsonhealthytransitioningtoadulthood,withprevalencerateshighestwithinthisagerange.Theagegroupselectedisexpectedtohavethecapacitytocompleteaself-guidedinterventionprogram.Recruitmenteffortswillbetakentoensureequivalentrepresentationofparticipantsunderandovertheageofmajority(18yearsold).2.4RacialandEthnicOriginRecruitmenteffortswillbetakentoensureadequaterepresentationofunderrepresentedracialandethnicminoritygroups.2.5InclusionCriteria1.13-21yearsofage2.PHQ-8score≥5ateligibilityscreening3.Englishfluencyandliteracy(participantandlegalguardian,ifapplicable)4.Accesstoacompatiblesmartphone(orotherdevice)andoperatingsystem(i.e.,capableofinstallingtheappfromtheGooglePlayorAppleAppStore;listwillbeprovidedonstudywebsite[app2])andregularinternetaccess5.Participantwillingandabletoprovideinformedconsent/assentandhavelegalguardianwillingandabletoprovideinformedconsent(ifrequired)6.UnderthecareofaUnitedStates(U.S.)-basedlicensedhealthcareproviderandwillingandabletoprovidecontactinformationfortheproviderandsignaHIPAAreleasethatallowsLimbixtocontactprovider7.Willingandabletoprovideinformationrequiredforstudyenrollment(e.g.allresponsestoinitialPHQ-8assessment,andcurrentantidepressantmedicationstatus)8.LocatedinthecontinentalU.S.,Hawaii,orAlaska,andnotplanningtoleavetheU.S.duringthestudyperiod(through1-monthfollowupassessments,upto11weeksaftereligibilityscreening)
LimbixHealthInc./1.0452.6ExclusionCriteria1.Diagnosisof(ortreatmentfor)bipolardisorder,posttraumaticstressdisorder,psychoticdisorder,substanceusedisorder,oreatingdisorderwithinthe12monthspriortoeligibilityscreening2.Changeinpsychotropicmedication(initiationorchangeindose)withinthe30dayspriortoeligibilityscreening3.Planstoinitiateorchangetreatment(e.g.,psychotherapy,psychotropicmedication,and/orotherpsychosocialtreatment)foramentalhealthdisorderduringthestudyinterventionperiod(5weeks)asdeterminedateligibilityscreening4.Suicideattemptwithinthepastyear5.Activesuicideideationwithintent6.PreviousparticipationinusertestingorclinicaltestingofSparkorSparkRx,orotherprevioususeofSparkRxapp7.Participationinanyotherclinicalresearchinvolvingamentalhealthinterventionortreatmentwithin60dayspriortoeligibilityscreening8.Planstoparticipateinanyotherclinicalresearchinvolvingamentalhealthinterventionortreatmentduringthestudyinterventionperiod(5weeks)asdeterminedateligibilityscreening9.Anycondition,comorbidity,oreventthat,intheopinionoftheinvestigator,willpreventtheparticipantfromadheringtotheprotocolorbenefittingfromtheintervention(e.g.,coercion,lowlevelofcognitivefunctioning)orwillpreventinvestigatorsfrombeingabletoensuresafety(e.g.,willbeleavingthecountryduringstudytimeperiod)10.Havingasiblingwhoisapastorcurrentparticipantinthestudy2.7VulnerableSubjectsChildrenbetweentheagesof13-17willbeincludedinthisresearchastheprogramtobeevaluatedisspecificallydesignedasaninterventionforadolescentswithsymptomsofdepression.Assentwillbeobtainedfromallchildrenunder18forstudyenrollmentunlesslegallyemancipatedorfinanciallyindependentinaccordancewithCAstateregulationsandregulationsofthestateinwhichtheminorresides.3.MethodsandProcedures3.1ProcedureRecruitmentParticipantswillberecruitedthroughcommunitysamplingandprovider-orhealthcaresystem-facilitatedcommunityrecruitment.Contractresearchorganizations(CROs)andotherreferral-basedrecruitmentcompaniesmaybeusedtocontactpotentialparticipants,providers,andhealthcaresystems.Recruitmentmethodsmayincludeproviderreferral,mediaandsocialmediaadsandposts;onlineadvertisement;flyersandotherphysicalads;wordofmouth;andoutreachtoproviders,communitymembers,andpotentialparticipantpools(includingbutnotlimitedtocaregivergroups,youthgroups,health-focusedgroupsandorganizations,schools,andhealthcaresystems).Providersmaybecompensatedatarateof$200/hourfortimespentassessingpreliminarypatienteligibilityandreferringpreliminarilyeligiblepatientstoLimbixforprescreening.Specifically,providerswhoarecompensatedwillbeaskedtocompleteareviewofstudyeligibilitycriteriaandindicatewhethertheirpatientispotentiallyeligibleforthestudy(Appendix8).Assessmentsofpreliminaryeligibilitycanbecompletedviachartrevieworviadiscussionwiththepatient.Potentiallyeligibleindividualswillbedirectedtothestudylandingpage.Potentialparticipants(andlegalguardians,ifapplicable)willbedirectedtoaweb-basedlandingpagewheretheywilleitherself-assesspreliminaryeligibilityusinganabbreviatedprescreeningformorbeaskedtoindicatewhethertheymeetsetsofeligibilitycriteriaviaafullprescreeningform(Appendix3).Ifpotentialparticipantscompletingtheprescreeningformindicatethattheyareineligible,theywillbedirectedtoalistof
LimbixHealthInc./1.046mentalhealthresources(Appendix4).Potentialparticipantswhoareunsureabouttheireligibilitycanreachouttoaresearchteammembertodiscussfurtherorwillbecontactedbyaresearchteammembertodeterminepotentialeligibility.Preliminarilyeligibleparticipants(andlegalguardians)willthenbepromptedtoscheduleavideoconferencingsessionwitharesearchcoordinatorinordertocompletetheconsentingprocess.Potentialparticipantswhoindicatethattheyareundertheageof18willbepromptedtoprovidecontactinformationforaparentorcaregiver,whowillbecontactedwithinformationaboutthestudyand/orthescheduledvideoconferencingsession.Theywillbeprovidedwithalinktoaccessavideopresentationdescribingallstudycomponents,participantrights,andcontentsoftheconsent/assentform,andwillbeaskedtoviewthevideoandanswercomprehensionquestionsembeddedwithinitbeforethevideoconferencingsession.Potentialparticipants(andlegalguardians)whohavenotviewedthevideopriortothevideoconferencingsessionwillviewitduringthesession.Ifparticipantsdonotattendtheirscheduledvideoconferencingappointment,theymaybesentanemailorSMSmessageallowingthemtorescheduletheirappointment.Consent,eligibilityconfirmation,andenrollmentAtthevideoconferencingsession,potentialparticipants(orlegalguardians,ifrequired)willconfirmtheiridentitybypresentinganapprovedformofU.S.identification.Theywillbeaskedtorescheduletheirappointmentiftheyareunabletodoso.Ifparticipantsundertheageof18donothavetheirlegalguardianpresent,theywillalsobeaskedtoreschedule.Potentialparticipants(andlegalguardians)willthenreceiveabriefoverviewofstudycomponents,duringwhichtheywillrespondtocomprehensionchecks,andhavetheopportunitytoclarifyanyquestionsorconcerns.Ifparticipants(andlegalguardians)didnotwatchthevideopresentationdescribingallstudycomponentsprovidedbeforethevideoconferencingsession,theywillwatchthevideoduringthevideoconferencingsessioninplaceofthisbriefoverview.ParticipantswillbeinformedthattheywillberandomlyassignedtoeithertheSparkRxortheeUConlyconditionandwillbeprovidedwithcomprehensiveinformationabouttheconsentformandtheirrightsasresearchparticipants(fordetails,seesection8.2).Afterprovidingtheirfullnamesandemailaddresses,aPart11compliantelectronicsignaturewillbeobtainedfromtheparticipant(orlegalguardian)todocumentconsent.Documentede-assentwillbeobtainedforparticipantsunder18yearsofage.Emancipatedminorsand/orminorswhoarefinanciallyindependentwillbeallowedtoprovideinformedconsentinaccordancewithfederalguidelines,CAstateregulations,andregulationsofthestateinwhichtheminorresides.Participantswhoturn18duringtheirparticipationinthestudywillbeaskedtoprovideinformedconsentoncetheyreachtheageofmajority.Followingconsent,participantsandlegalguardianswillbeaskedtoprovidetheirpreferredemailaddress,preferredphonenumberforreceivingtextmessages,informationabouttheirmobiledevice,homeaddress,currentaddress(incasesafetyconcernsarise),andemergencycontactinformation.Participantswillberequiredtoprovidethenameandcontactinfofortheirhealthcareprovider.ToconfirmthatprovidersarelicensedintheU.S.,researchcoordinatorswillsearchfortheproviderintheNationalProviderIdentifier(NPI)recordsdirectory(https://npiregistry.cms.hhs.gov/search).Ifaparticipantisunabletoprovidetheirhealthcareprovider’scontactinfo,ortheresearchcoordinatorisunabletoconfirmtheprovider’sNPIrecord,theparticipantwillbeaskedtoprovidetheinformationofanotherhealthcareprovider.Iftheparticipantisunabletodoso,theywillbeinstructedtorescheduletheappointmenttoatimewhentheycanprovideanotherprovider’sinformation,ortheywillbedeemedineligible.Participants(orlegalguardians)willbeaskedtosignaHIPAAreleaseformtoallowLimbixtocontacttheirhealthcareproviders.ToconfirmthatparticipantsarelocatedintheUnitedStates,theywillbeaskedtoprovidetheInternetProtocol(IP)addressofthedevicetheyareusingduringthevideoconferencingsession.ResearchstaffwilldeterminewhethertheIPaddressislocatedwithintheU.S.byenteringitintoaknownlookupwebsite.IPaddresslookupisgenerallyaccurate(>90%)fordeterminingwhetheradeviceislocatedwithinoroutsidetheU.S.However,becauseIPaddressesarenotperfectindicatorsoflocation,ifparticipantsinsistthattheyarewithintheU.S.despiteprovidinganon-U.S.-basedIPaddress,theenrollmentwillcontinuewiththeprovision
LimbixHealthInc./1.047thatfurtherchecksofIPaddresswillbeconductedusinglocationinformationalreadycollectedthroughthesecurewebportalandapp.ParticipantswhoselocationcannotbeconfirmedtobewithintheU.S.willbedroppedfromthestudy,assafetycannotbeappropriatelymonitoredandensuredfortheseindividuals.Aparticipantaccountinasecurewebportalwillbecreatedwithausername(useremailaddresses)andatemporarypassword.Potentialparticipantswilllogintotheportalandwillbeinstructedtochangetheirpassword.Intheportal,potentialparticipantswillcompletetwoformsneededtodetermineeligibility:thePHQ-8andtheMedicationUseScreener(seeAppendix1).PotentialparticipantswhodonotmeetcriteriaforparticipationbasedonthePHQ-8(score<5)orwhodonotwishto(orcannot)respondtotheMedicationUseScreenerwillbeinformedoftheirineligibilityanddirectedtomentalhealthresources.Participantsandlegalguardians(ifapplicable)willthenbeaskedtoverballyconfirmthattheymeeteacheligibilitycriterion.Toensureprivacy,legalguardianswillbeaskedtoleavetheroomunlesstheparticipantindicatesthattheywanttheirguardianpresent.Afterconfirmingeligibilitywiththeparticipant,thelegalguardianwillbeaskedtoreturnandconfirmtheeligibilityoftheirchild.Participantswhoreportahistoryofsuicidalideationorself-harmurgeswillbepromptedtocompleteasafetyplanincollaborationwiththeresarchcoordinatorand/orstudyclinician(Appendix5).Ifparticipantsendorseactivesuicidalideationwithintentduringthissession,theywillbedirectedtoseekanemergencypsychiatricevaluationforfurtherassessmentoftheirriskandappropriateintervention(seesection4.8.1).Participants(orlegalguardians)whoindicateineligibilitytoparticipateduetoanyoftheothereligibilitycriteriawillbedirectedtoalternativementalhealthresourcesandwillbeineligibletocontinuewithparticipation.Participantswhoareineligibleasaresultofhavinganincompatiblemobiledevice/operatingsystemwillbesentanemailofferingtheopportunitytoscheduleanothervideosessioniftheirdevice/operatingsystemchanges.Alleligibleparticipantswillbeprovidedwithasafetyplandocumentandinstructionsforcompletingandusingthissafetyplandocumentshoulditbenecessary(Appendix5).Anemailedortextremindertocompletethisplanmaybesentfollowingtheconsentsession.Participantswillbeaskedtoindicateinweeklyparticipantsymptomchecks(PSCs;seeAppendix1)ortonotifythestudyteamiftheirtreatmentforsymptomsofdepressionoranyotherhealthconditionchangesduringthestudy,oriftheyparticipateinanyothertreatment/interventionresearchstudy.Participantswillbeencouragedtofollowtheadviceoftheirdoctorregardingallmedicaldecisions.Participantswillbetoldthatthisisablindedstudy,meaningthatmostofthestudystaffwithwhomtheyinteractafterrandomizationwillnotknowwhethertheyreceivedtheSparkRxappornot.Theywillbeprovidedwithcontactinformationiftheyneedtoreachoutforapporwebportaltroubleshooting,orwithquestionsabouttheirparticipationinthestudy.Aftereligibilityisconfirmed,anaccountforlegalguardians(ifapplicable)inthesecurewebportalwillbecreatedwithusernames(useremailaddresses),andlegalguardianswillbeprovidedatemporarypasswordtologintochangetheirpassword.Participantsandlegalguardians(ifapplicable)willbedirectedtocompletebaselineassessmentsinthesecurewebportal.Uponcompletionofbaselineassessments,participantswillberandomized(1:1)toeithertheSparkRxconditionortheeUConlycondition(seedescriptionsbelow).Randomizationwillbestratifiedbyparticipant-reportedantidepressantmedicationstatus([yes,no]fromtheMedicationUseScreener)andparticipant-reportedbaselinePHQdepressionseverity(low:PHQ-8score<15;high:PHQ-8score≥15).Participantswillreceiveinstructionsonhowtodownloadandlogintotheirassignedmobileapp.Followingrandomizationandappdownload,thesessionwillend.Additionalinformationwillbesenttoparticipantsviaemail.Followingthevideoconferencingsession,researchcoordinatorswillcontactparticipants’healthcareproviderofficesandindicatethatthepatienthasenrolledinthisresearchstudy.Ifinformationisvolunteeredtotheresearchcoordinatorthattheparticipantisnotapatientofthehealthcareprovider,theparticipantwillbecontactedtoprovideinformationforanalternativehealthcareprovider.AsparticipantsafetymaybecompromisedintheabsenceofaknownU.S.-basedhealthcareprovider,participantswillbedroppedfromthe
LimbixHealthInc./1.048studyifcontactinformationforanalternativehealthcareproviderisnotobtained.InterventionPeriodSparkRxgroup:TheSparkRxmobileprogramwillbe5weeksindurationandself-guided.Thefivemodulesinthisprogramareeachexpectedtotakearound60minutestocomplete.Modulesdonotneedtobecompletedinasinglesessionbutcanbecompletedoverthecourseofseveraldays.Emergencyresourcesforparticipantsexperiencingthoughtsofsuicideorself-harmwillbeavailableintheapp.Whileparticipantscanprogressthroughtheprogramsattheirownpace,participantswillbeinstructedtocompleteonemoduleinthemobileappperweek,andtocompletetheprogramwithinthe5-weekinterventionperiod.ParticipantswillbepromptedtocompleteweeklyPHQ-8andPSCinthemobileapplication.Appnotifications,text(SMS)and/oremailmessagesmaybesenttoparticipantstoencouragethemtocompletetheweeklyassessments(i.e.,PHQ-8andPSC).Toencourageparticipantstoengagewiththeapp,automatedappnotificationswillalsobesent.Forparticipantsunder18yearsofage,legalguardiansmayreceiveemailand/ortextnotificationstocompleteproxyPHQ-8andPSCassessmentsinthesecurewebportal.eUCgroup:Participantswilldownloadamobileappthatcontainsnocontent,butthatprovidesaccesstoin-appweeklyPHQ-8andPSCassessments.Allparticipantswillreceivenotifications(appnotificationsandSMSand/oremail)tocompletethePHQ-8andPSC).Forparticipantsunder18yearsofage,legalguardiansmayreceiveemailand/ortextnotificationstocompleteproxyPHQ-8andPSCassessmentsinthesecurewebportal.Post-interventionperiodAfterthe5-weekinterventionperiod,allparticipantswillbesentlinksviaemailand/ortexttocompletepost-interventionself-reportquestionnairesinthesecurewebportal.Participantsmayreceiveautomatedemailandtextreminderstocompletethepost-interventionquestionnaires.Astudycoordinatormayalsocontactparticipants(andlegalguardians)whohavenotcompletedpost-interventionquestionnairesbeforetheyreacha2weekdeadline.Onemonthaftertheendoftheinterventionperiod,participantswillbepromptedtocompleteself-reportquestionnairestoevaluatesustainedeffectsoftheinterventiononrelevantoutcomes.Participantsmayreceiveautomatedemailandtextreminderstocompletethequestionnaires.Astudycoordinatormaycontactparticipants(andlegalguardians)whohavenotcompletedfollow-upquestionnairesbeforetheyreacha2weekdeadline.Participantswhodonotcompletetheone-monthfollow-upquestionnaireswithin2weekswillbeconsideredlosttofollow-up.Ifaparticipantchoosestowithdrawfromthestudyatanypointortheparticipantisdroppedfromthestudyduringtheinterventionperiod(5weeks),accesstothewebportalandmobileappwillberestrictedatthattime;otherwiseaccesstothemobileappwillberestrictedattheendofweek5andaccesstothewebportalwillberestrictedafter1-monthfollow-upassessmentshavebeencompletedortheparticipantisdeemedlosttofollow-up.AllrelevantFDArequirementsfortheconductofclinicaltrialswillbefollowed,includingregistrationonclinicaltrials.gov.EmailandothernotificationtemplatesareprovidedinAppendix6.3.2DescriptionoftheLimbixSparkRxProgramTheSparkRxprogramisa5-weekprogramdividedinto5levelsintendedtobecompletedweekly.Acharactercalled'Limbot'isusedasaguide.Limbotencouragestheuserincompletingthebehavioralactivationprogramandprovidespersonalexamplesofhowtheyhaveundertakenbehavioralactivationtherapy.ParticipantsareinstructedtocompleteaweeklyPHQ-8assessmentandPSCinthemobileapp.Tasksinthemobileapp
LimbixHealthInc./1.049progressinalinearfashion--i.e.,eachtaskmustbecompletedtoprogresstothenexttask.Certainon-demandresourcescanbeaccessedintheappatanytime,includingcrisisresources.Textentriesthatmatchadatabaseofconcerningwords/phraseswilltriggeranautomatedpop-upsuggestingparticipantsvisitthein-appcrisisresourcesiftheyneedadditionalsupport.Studystaffwillmonitorparticipants’freeformtext,symptomdeterioration,pop-upalerts,andquestionnairedataforsafety.3.3Descriptionofassessment-enhancedUsualCare(eUC)UCisbasedonasteppedcaremodelfortreatmentforsymptomsofdepression.Itcanincludeanyofthefollowing:activemonitoringofdepressivesymptomsandsuicidality,supportivecounselingbyahealthcareprovider,psychosocialsupportinterventions,collaborativecare(e.g.facilitationofparentalandpatientself-management,referralforpeersupportorothercommunityorschool-basedbehavioralhealthprograms),psychoeducation,complementaryandalternativemedicineapproaches,psychotherapy(e.g.behavioraltreatment,interpersonaltherapy,cognitivebehavioraltherapy),pharmacotherapyformoodproblems,visittoaprimarycareprovider,behavioralormentalhealthspecialistortherapist,counselororcoachformooddisorder.Forpurposesofthisstudy,UCwillbeenhancedbypromptingparticipantstocompleteweeklyPHQ-8andPSCassessmentsinamobileapp.Studystaffwillmonitorparticipants’symptomdeteriorationandquestionnairedataforsafety.3.4AssessmentsThefollowingPrescreening,Baseline,post-intervention,andfollow-upassessmentswillbecompletedviasecurewebportal.Weeklyparticipantassessments(PHQ-8,PSC)willbecompletedinthemobileapp.Weeklylegalguardianassessments(PHQ-8,PSCproxies)willbecompletedviathesecurewebportal.AllassessmentsareprovidedinAppendix1,withtheexceptionofthePrescreeningQuestionnaire(Appendix3).Table1.ScheduleofAssessmentsEligibilityScreeningBaselineWeeklyduringinterventionperiodPost-intervention1-monthfollow-up(4weekspostintervention)PrescreeningQuestionnaireX(ifused)PatientHealthQuestionnaire(PHQ-8)XXXXMedicationUseScreenerXBaselineQuestionnaireXBaselineQuestionnaire,legalguardianproxy*XPatientHealthQuestionnaire(PHQ-8,legalguardianproxy*)XXXXBehavioralActivationforDepressionScale-shortform(BADS)XXXGeneralizedAnxietyDisorder(GAD-7)XXXPediatricQualityofLifeEnjoyment&SatisfactionQuestionnaire(PQ-LES-Q)XXXPediatricQualityofLifeEnjoyment&SatisfactionQuestionnaire(PQ-LES-Q,legalguardianproxy*)XXXParticipantSymptomCheck(PSC)XXX
LimbixHealthInc./1.0410ParticipantSymptomCheck(PSC,legalguardianproxy*)XXXPost-InterventionQuestionnaireXPost-InterventionQuestionnaire,legalguardian*XSystemsUsabilityScale(SUS)XUserEngagementScale(UES-SF)X1monthfollow-upQuestionnaireX1monthfollow-upQuestionnaire,legalguardian*XAbsenteeismQuestionnaireXXXHealthcareUtilizationQuestionnaireXXXAbsenteeismQuestionnaire,legalguardian*XXXHealthcareUtilizationQuestionnaire,legalguardian*XXX*Onlyadministeredwhenparticipantsareunder18yearsofageDescriptionofAssessments●ThePrescreeningQuestionnaireisadministeredtopotentialparticipantsonthestudywebsitelandingpageandassesseswhetherornotparticipantsarepreliminarilyeligibletoparticipatebasedonyes/no/unsureresponsestoclusteredsetsofeligibilitycriteria(Appendix3).●ThePatientHealthQuestionnaire(PHQ-8)ParticipantandLegalGuardianProxyisan8-itemparticipant-reportmeasureforscreeningfordepressionandforestablishingdepressionseverity100.Thetotalscorerangesfrom0-24,withahigherscoreindicatinggreaterdepressionsymptomseverity.Forparticipantsunder18,alegalguardianproxyversionofthePHQ-8willbeadministeredtolegalguardians.Clinicallysignificantimprovementisdefinedasareductioninassessmentscore≥5101.Interventionresponseisdefinedas50%reductioninsymptomsfrompre-topost-intervention,andremissionisdefinedasascore<5followingintervention102.●MedicationUseScreenerisasingle-itemscreeningformthatasksparticipantstoreportwhetherornot(yes/no)theyarecurrentlytakingpsychotropicmedicationforthetreatmentofdepressionorsymptomsofdepression.●7itemGeneralizedAnxietyDisorderscale(GAD-7).TheGAD-7isavalidated7-itemparticipant-reportedassessmentforgeneralizedanxietydisorder103.Wewillevaluatechangesinanxietysymptomsgiventhehighcomorbiditybetweenanxietyanddepression.Thetotalscorerangesfrom0-21,withahigherscoreindicatinggreateranxietysymptomseverity.●PediatricQualityofLifeEnjoyment&SatisfactionQuestionnaire(PQ-LES-Q)Participant&LegalGuardian:A15-itemparticipant-reportedself-administeredquestionnairethatcaptureslifesatisfactionoverthepastweek104.Eachquestionisratedona5-pointscalefrom1(VeryPoor)to5(VeryGood).Thefirst14itemsaresummedtoformatotalscorerangingfrom14-84,withhigherscoresindicatinghigherqualityoflife.The15thitem(“Overall,howhasyourlifebeen?”)isastand-aloneitem.Forparticipantsunder18,alegalguardianproxyversionofthePQ-LES-Qwillalsobeadministeredtolegalguardians.●ParticipantSymptomCheck(ParticipantandLegalGuardian).Assesseslegalguardian-andparticipant-reportednegativesymptomsandchangesintreatmentsincethelastcheck-in,usingmultiplechoiceandfree-formtextresponses.●BehavioralActivationforDepressionScale-ShortForm(BADS).TheBADS105consistsof9participant-reportedquestionsassessingbehavioralactivationandavoidanceoverthepreviousweek,eachratedona7-pointscalerangingfrom0(notatall)to6(completely).Thisformcanbeusedtotrackbehaviorshypothesizedtounderliedepressionandspecificallytargetedforchangebybehavioralactivation.Itexamineschangesinthefollowingareas:activation,avoidance/rumination,work/schoolimpairment,andsocialimpairment.Thetotalscorerangesfrom0to54,withhigherscoresindicatinghigheractivation.●BaselineQuestionnaire(ParticipantandLegalGuardian).Thisparticipant-andlegalguardian-reportedquestionnaireincludesparticipantage,sex,gender,socio-economicstatus,medical
LimbixHealthInc./1.0411history,andmedications.●Post-InterventionQuestionnaire(ParticipantandLegalGuardian).Thisparticipant-andlegalguardian-reportedquestionnaireassessesfeedbackonthemobileapp.●SystemUsabilityScale(SUS).TheSUS106isaparticipant-reportedscalethatprovidesaquick,reliabletoolformeasuringtheusabilityofthemobileapp.TheSUSconsistsofa10-itemquestionnairewithfiveresponseoptionsforrespondents,rangingfromStronglyAgreetoStronglyDisagree.Thetotalscorerangesfrom0-100,withhigherscoresindicatinggreaterusability.●UserEngagementScale-ShortForm(UES-SF).TheUES-SF107isaparticipant-reported,statisticallyreliablemeasureofself-reporteduserengagementthatistailoredtothespecificdevicebeingtested(i.e.,thestudyapp).Theformhas12itemsandusesa5-pointLikertscale.Thereare4subscales:Aestheticappeal,focusedattention,perceivedusability,andreward.Eachsubscalescorerangesfrom1-5,withhigherscoresindicatinghigherlevelsofeachscale.Thetotalscorealsorangesfrom1-5,withhigherscoresindicatingmoreengagement.●Onemonthfollow-upQuestionnaire(ParticipantandLegalGuardian).Thisparticipant-andlegalguardian-reportedquestionnaireassessesfeedbackonthemobileapp.●AbsenteeismQuestionnaire(ParticipantandLegalGuardian)Thisparticipant-andlegalguardian-reportedquestionnaireassessesmissedtimeatworkand/orschoolattributabletotheparticipant’smentalhealthconditionoverthepast4weeks.●HealthcareUtilizationQuestionnaire(ParticipantandLegalGuardian)Thisbriefparticipant-andlegalguardian-reportedquestionnaireassessesuseofhealthcareresourcesoverthepast4weeks.4.DataAnalysisandDataMonitoring4.1PrimaryOutcome●Theprimaryoutcomemeasureisdepressivesymptomseverity(PHQ-8score),whichwillbeusedtocomputedifferencesinmeandepressivesymptomsbetweenparticipantsrandomizedtotheSparkRxconditionandthoserandomizedtotheeUCconditionatpost-intervention(5weeks).PHQ-8scorewillalsobeusedtodeterminewhetherthereisclinically-meaningfulreductioninseverityintheSparkRxgroupatpost-intervention.Clinically-meaningfulreductioninseverityisdefinedasa5pointorgreaterdecreaseinPHQ-8scorefrombaseline.4.2SecondaryOutcomes●Interventionresponseatpost-intervention(50%reductioninPHQ-8scorefrombaseline)●Remissionatpost-intervention(PHQ-8score<5)●Clinically-meaningfulreductioninseverityatpost-intervention(≥5pointreductioninPHQ-8scorefrombaseline)4.3Tertiary/ExploratoryOutcomes●Legalguardian-reportedPHQ-8scoreatpost-intervention●Anxietysymptoms(GAD-7)atpost-intervention●Participant-andlegalguardian-reportedglobalfunctioning(PQ-LES-Q)atpost-intervention●Participant-andlegalguardian-reportedabsenteeismatpost-intervention●Participant-andlegalguardian-reportedhealthcareutilizationatpost-intervention●Behavioralactivation(BADS)atpost-intervention●Participant-reportedappusabilityandengagement(SUS,UES-SF)●Primary,secondary,andtertiary/exploratoryoutcomesat1-monthfollow-up(asappropriate)4.4InterventionComplianceOutcomes●Interventionadherence(ratesofmoduleandprogramcompletion)forSparkRxgroup●Appusage(dailyactiveusers,minutesspentinapp)forSparkRxgroup4.5SafetyOutcomes●Numberofadverseevents(AEs),numberofparticipantswithAEs,andratesofAEsbasedon
LimbixHealthInc./1.0412PHQ-8-basedsymptomdeteriorationandresponsestoweeklyPSCquestionnaires(bothgroups)●NumberofAEs,numberofparticipantswithAEs,andratesofAEsbasedonin-appfreeformtext(SparkRxgrouponly)●Numberofadversedeviceeffects(ADEs),numberofparticipantswithADEs,andratesofADEs(SparkRxgrouponly)4.6SampleSizeSamplesizecalculationisbasedonprimaryoutcomePHQ-8atpost-intervention.SixPHQ-8measurementswillbecollectedfromeachsubject(baselineandweeklyduringthe5-weekinterventionperiod).Usingatwo-samplet-testapproach,assumingatwo-tailedalphasetat0.05,atotalof200participants(100ineachstudyarm)willgiveus80%powertodetectamoderateeffectsizeofatleastd=0.4.Givenananticipated10%rateofattrition,weaimtoenroll220totalparticipantsinthestudy.4.7DataAnalysisDetailedstatisticalanalysisplans(SAP)willbedevelopedpriortocompletionofprimaryoutcomedatacollection.Priortoanalysis,studypopulationdetailsincludingthenumberrandomizedtoeachstudyarmandlosttofollow-upwillbedescribed.BaselineparticipantcharacteristicswillbesummarizedfortheSparkRxandeUCarmsasmeans,standarddeviations,medians,25thand75thpercentilesforcontinuousvariables,andascountsandpercentagesforcategoricalvariables.Differencesinbaselinecharacteristicsbetweenthegroupswillbeexploredusingtabularandvisualdisplays,asappropriate,andappropriatestatisticaltests(e.g.,independentsamplet-testsforcontinuousvariables,chi-squaretestsforcategoricalvariables).4.7.1GeneralApproachAnalysisPopulations:Allanalyseswillbecompletedinlinewiththeintention-to-treat(ITT)principle,whereallparticipantswillbeincludedintheanalysesaccordingtotheirassignedstudyarmatbaseline,regardlessofadherencetostudyprotocol.Per-protocolanalyseswillalsobeconductedtoestimatetreatmenteffectsforparticipantswhoadheredtotheprotocol,andwillincludeindividualswhocompletedtheBaselineandpost-interventionPHQ-8assessmentsand,forparticipantsintheSparkRxgroup,metaminimumengagementthresholdofcompletingtwomodules.DescriptiveStatistics:Fordescriptivestatistics,thefollowingwillbereported:Continuousdata:n,mean,standarddeviation,medianandinterquartilerange,minimumandmaximumCategorical:n/NandpercentageoftotalperarmMissingData:Wedonotanticipatemissingdataforthestratificationvariables,whichwillbeincludedascovariatesintheanalysismodels.Ongoingeffortswillbemadetoreducetheamountofmissingdataforalloutcomes.Despitetheseefforts,missingdataforprimary,secondary,andtertiary/exploratoryoutcomesarelikely.Datamissingatrandom(MAR)ondependentvariablesareeasilyhandledinrepeatedmeasuresmixedmodelssonoimputationwillbeneeded.Forallotherstatisticalanalysesdescribedbelowandmissingdataoncovariates(orindependentvariables)inmodels,multipleimputationwillbeusedifatleast5%ofdatapointsaremissingforagivencovariateorvariable.Caseanalysisorsingleimputationmethodsmayalsobeusedandaspecificapproachforimputationwillbeselectedbasedonkeyattributesoftheobtaineddata,includingpercentmissingandwhetherdataaremissingatrandom.Wewillcomparetheresultsobtainedwithandwithoutimputation.SensitivityanalyseswillbeusedtoassesstheimpactofpotentialdeviationsfromtheMARassumptiononthestudyfindings.4.7.2AnalysisofPrimaryOutcomeTotesttheprimaryhypothesisthattherewillbeadifferencebetweentheSparkRxandeUCarmssuchthatparticipantsrandomizedtoreceiveSparkRxwillhavelowerPHQ-8scoresatpost-intervention,wewillimplementamixedeffectmodelwithappropriatecorrelationmatrix.Time(i.e.,dayafterBaselinesession[T=0]thateachPHQ-8wascompleted),interventionarm,timebyinterventioninteraction,baselinePHQ-8score,andantidepressantmedicationstatus(variableusedforrandomization)willbeincludedinthemodelasfixedeffects.WewilltestdifferentcorrelationmatricessuchasUN,CS,AR(1),andselectthebestcorrelation
LimbixHealthInc./1.0413structureforourdata.Thehypothesiswillbetestedastwo-sidedwithasignificancelevelof0.05.ThisprimaryanalysiswillbeconductedaccordingtotheITTprinciplewithparticipantsanalyzedandoutcomesattributedaccordingtothetreatmentarmtowhichtheparticipantswererandomized,regardlessofpost-randomizationcompliance.Wewilladditionallydeterminewhetherthestatedthresholdforclinically-meaningfulreductioninseveritybasedonPHQ-8(reductioninscore≥5frombaseline)isincludedorsurpassedby95%confidenceintervalsaroundtheaveragePHQ-8reductionintheSparkRxarm.4.7.3AnalysisofSecondaryOutcomesWewillcomputethenumberandproportionofparticipantsmeetingcriteriaforinterventionresponse,remission,andclinically-meaningfulreductioninseverityatpost-interventionforeachgroup,andcompareratesbetweengroupsusingchi-squaretests.Wehypothesizethattherewillbehigherratesofinterventionresponse,remission,andclinically-meaningfulreductioninseverityintheSparkRxarmthanintheeUCarm.4.7.4AnalysisofTertiary/ExploratoryOutcomesForeachcontinuousoutcome(e.g.,GAD-7,BAD,PQ-LES-Q),scoresatpost-interventionwillbecomparedbetweengroupsusinganalysisofcovariance(ANCOVA)models,withbaselinescoresincludedasacovariate.Totestthehypothesisthatlegalguardian-reporteddepressionsymptoms(PHQ-8proxy)willbelowerfortheSparkRxgroupthantheeUCgroupatpost-intervention,wewillimplementamixedeffectmodelwithappropriatecorrelationmatrixasdescribedabove(4.7.2).Moderationanalyseswillbecarriedouttodetermineifandhowparticipantcharacteristics(baselinePHQscore,antidepressantmedicationuse,sex/gender,andage)influenceinterventioneffectsonPHQ-8scoresatpost-intervention.Mediationanalysiswillbecarriedouttodeterminewhetherinterventionengagement(e.g.,modulecompletionrate,durationofuse,timetocompleteprogram)mediatestheeffectofinterventiononPHQ-8scoresatpost-intervention.Changesinhealthcareutilizationandabsenteeismfrombaselinetopost-interventionwillbeexamineddescriptively.Ratingsofappusabilityandengagement(SUS,UEF-SF)willbeexamineddescriptivelyfortheSparkRxgrouponly.Outcomescollectedatthe1-monthfollow-uptimepointwillbeanalyzedasabove.4.7.5AnalysisofInterventionComplianceOutcomesWewillevaluateinterventioncompliancedescriptivelybycomputingdailymobileappusageandtimespentintheappfortheSparkRxgroup.Likewise,rateofmodulecompletion(reachingtheendofanentiremodule)andprogramcompletion(reachingtheendofthefinalmodule)fortheSparkRxgroupwillbeexamineddescriptively.4.8DataMonitoringThisisalowriskresearchstudy.ThedataandsafetymonitoringplanfortheproposedstudywillincludemonitoringofadverseeventsandadversedeviceeffectsbyaMedicalExpert,anindependentexternalclinician,aswellasbyanindependentDataandSafetyMonitoringBoard(DSMB).Thefollowingprocedureswillbefollowed,incompliancewithIRBrequirements,toensurethesafetyofstudyparticipantsandthevalidityandintegrityofdata.Becausetheinvestigationaldeviceisanon-significantriskdevice,theMedicalExpertwillnotbeoncall24/7.Thestudyinvestigators,MedicalExpert,andstudyclinicianswillregularlymonitorpotentialrisksandproceduresforprotectingrisk.Studyinvestigatorsandappropriatestudypersonnelwillevaluatetheprogressofthestudy,includingperiodicassessmentsofdataqualityandtimeliness,participantrecruitment,accrualandretention,participantriskversusbenefit,andotherfactorsthatmayaffectstudyoutcome.Theywillalsoconsiderfactorsexternaltothestudy,suchasscientificortherapeuticdevelopmentsthatmayhaveanimpact
LimbixHealthInc./1.0414onthesafetyoftheparticipantsortheethicsofthestudy.OngoingqualitycontrolwillalsoincluderegulardataverificationandprotocolcompliancecheckstobeperformedbythePIsandappropriatestudypersonnel.Anongoingreviewofstudyprocedureswillbecarriedouttoensurethattheprivacyofparticipantsandconfidentialityofdataasoutlinedinthestudyprotocolandconsentformarenotviolated.Therewillalsobeprovisionsformonitoringthecollecteddatatoensurethesafetyofparticipantsandtomaintaintheconfidentialityoftheresearchdata.Thisstudymaybestoppedpriortoitscompletionif:1)studyrecruitmentorretentionistoolowforthestudytoprovidemeaningfulresults;2)newinformationbecomesavailableduringthetrialthatnecessitatesstoppingthetrial;3)othersituationsoccurthatmightwarrantstoppingthetrial.ThetrialwillbestoppedearlyifPIs,incollaborationwiththeMedicalExpertandtheindependentDSMB,findthattheharmtostudyparticipantsoutweighsthebenefitofthescientificevidencetobeaccruedbycontinuingthetrial.PIsalongwiththeMedicalExpertandstudyclinicianswillprovidecontinuous,closemonitoringofallreportedadverseevents(AEs)andadversedeviceeffects(ADEs).IncompliancewithIRBandDSMBguidelines,investigatorswillreportadverseeventsandadversedeviceeffectsasrequired.Anadverseeventisdefinedasanyunwantedmedicaloccurrencethatoccursduringthestudy.Anadversedeviceeffect(ADE)isanadverseeventrelatedtotheuseofaninvestigationalmedicaldevice.Thisincludesanyadverseeventresultingfrominsufficienciesorinadequaciesintheinstructionsforuse,thedeployment,theinstallation,theoperation,oranymalfunctionoftheinvestigationalmedicaldevice.Thisalsoincludesanyeventthatisaresultofausererrororintentionalmisuse.Forthisstudy,ADEsmayoccurinonlytheSparkRxarm.Anadverseeventoradversedeviceeffectisconsideredseriousifitmeetsanyofthefollowingcriteria:●Isfatal;●Islife-threatening,meaning,theparticipantwas,intheviewoftheinvestigator,atimmediateriskofdeathfromthereactionasitoccurred;●Leadstopersistentorsignificantdisability/incapacity,i.e.,theeventcausesasubstantialdisruptionofaperson’sabilitytoconductnormallifefunctions;●Requiresorprolongsinpatienthospitalization;●Isanimportantmedicalevent,basedonappropriatemedicaljudgment,thatmayjeopardizetheparticipant,ortheparticipantmayrequiremedicalorsurgicalinterventiontopreventoneoftheotheroutcomesabove.○Note1:Plannedhospitalizationforapre-existingcondition,oraprocedurerequiredbytheinvestigationalprotocol,withoutseriousdeteriorationinhealth,isnotconsideredaseriousadverseevent.○Note2:Seriousadversedeviceeffect(SADE):adversedeviceeffectthathasresultedinanyoftheconsequencescharacteristicofaseriousadverseevent.ThedegreeofcertaintyofcausalrelationshipofanADEtothemobileinvestigationaldevicewillberatedasfollows:●NotPossible:Aneventthatisnotduetotheuseofthestudydevice.Analternativeexplanation,e.g.,concomitantdrug(s),concomitantdisease(s)isclear.●Possible:Aneventthatmightbeduetotheuseofthestudydevice.Analternativeexplanation-e.g.,concomitantdrug(s),concomitantdisease(s)-isinconclusive.Therelationshipintimeisreasonable;therefore,thecausalrelationshipcannotbeexcluded.●Probable:Aneventthatmightbeduetotheuseofthestudydevice.Analternativeexplanationislesslikely-e.g.,concomitantdrug(s),concomitantdisease(s).Therelationshipintimeissuggestive.●Definitely:Aneventthatisduetotheuseofthestudydevice.Theeventcannotbereasonably
LimbixHealthInc./1.0415explainedbyanalternativeexplanation-e.g.,concomitantdrug(s),concomitantdisease(s).UnanticipatedAdverseDeviceEffects(UADEs,asdefinedin21CFR812.3,alsoreferredtoas“UnanticipatedProblems”):Anyseriousadverseeffectonhealthorsafetyoranylife-threateningproblemordeathcausedby,orassociatedwith,adevice,ifthateffect,problem,ordeathwasnotpreviouslyidentifiedinnature,severity,ordegreeofincidenceintheinvestigationalplanorapplication;ORanyotherunanticipatedseriousproblemassociatedwithadevicethatrelatestotherights,safety,orwelfareofsubjects.UADEsmustmeetallthefollowingcriteria:●Serious(asdefinedabove)●Associatedwiththedeviceunderinvestigation(possibly,probably,ordefinitely)●UnexpectedNoseriousADEsareexpected.Giventhatpsychotherapyandpsychoeducationcanleadindividualstothinkmoreabouttheirdepressivesymptoms,expectedADEsmayincludetemporaryclinicallysignificantdeteriorationindepressivesymptomsandworseningmood.AnticipatedAEs,giventhestudypopulation,includesuicidalideation,non-suicidalselfinjuryideation,non-suicidalselfinjury(NSSI)thatdoesnotresultinmedicalattention,clinicallysignificantdeteriorationindepressivesymptoms.AnticipatedseriousAEsthatwouldbeseeninthispopulationindependentofthestudy,includeactivenonsuicidalselfinjuryresultinginmedicalattention,suicideattempts,deathbysuicide,and/orinpatienthospitalizationunrelatedtoplannedhospitalizationforapre-existingcondition.SeriousAEswillbereportedbiannuallytotheDSMBandtotheIRBperlocalpolicyandaspartofannualreportingunlesstheymeetthedefinitionofanUADEorunanticipatedproblem.TheseriousnessofanAEorADEwillbepreliminarilydeterminedbystudyclinicians,butfinaldeterminationwillbeprovidedbyanindependentexternalcliniciantoeliminatebiasinclassification.AllAEsmusthavetheirrelationshiptotheinvestigationaldevicesassessedbyanexternalclinicianbasedonthetemporalrelationshipandhis/herclinicaljudgment.ThestudycliniciansandMedicalExpertwillberesponsiblefordeterminingwhetheranADEisexpectedorunexpected.AnADEwillbeconsideredunexpectedifthenature,severity,orfrequencyoftheeventisnotconsistentwiththeriskinformationpreviouslydescribedforthestudyintervention.AllAEs,ADEs,andcomplaintswillberecorded.TheexternalclinicianandtheMedicalExpertwilldeterminewhetheritisintheparticipant’sbestinteresttoremaininthestudyafteranyseriousAEorUADEandnotifythePIaccordingly.StudyPIswillreportUADEstotheIRBandDSMBwithin10workingdays.LimbixwillimmediatelyconductanevaluationofanyreportedUADEsandwillreportsucheffectstotheFDAwithin10workingdays.IfitisdeterminedthatanUADEpresentsanunreasonablerisktosubjects,theinvestigationorpartsoftheinvestigationpresentingthatriskwillbeterminatedassoonaspossible.Terminationshalloccurnotlaterthan5workingdaysafterthesponsormakesthisdeterminationandnotlaterthan15workingdaysafterthesponsorfirstreceivesnoticeoftheeffect.LimbixwillnotresumeaterminatedinvestigationwithoutIRBapprovaland,iftheinvestigationwasterminatedunderparagraph(b)(2)of21CFR812.46,FDAapproval.Per21CFR56.108(b)(1)and21CFR812.150(a)(1),PIswillreportanyunanticipatedprobleminvolvingrisktohumansubjectsorotherstotheIRBnolaterthan10businessdaysfromthetimeofidentification.Anunanticipatedproblemmustmeetallthefollowingcriteria:●Unexpected(intermsofnature,severity,orfrequency)giventheinformationprovidedinresearch-relateddocumentsandthecharacteristicsofthesubjectpopulationbeingstudied;●Relatedorpossiblyrelatedtoparticipationintheresearch;AND●Suggeststhattheresearchplacessubjectsorothersatagreaterriskofharmthanwaspreviously
LimbixHealthInc./1.0416knownorrecognized.4.8.1StudyStaffResponsibilitiesIfsuicideideationisendorsedatanypointduringthestudy,asafetyprotocolwillbeinitiated.Ifparticipantsarefoundtohaveahighsuiciderisk,theywillbeexcludedfromtheresearchstudyandparticipantswillbedirectedtoappropriatelocalresources.Aparticipanthashighriskforsuicideiftheyendorseideationwithaplanorintent.AllsafetyincidentswillbedocumentedandreportedtotheDSMB,IRB,andFDAasneeded.Ifsafetyrisksrelatedtosuicidalityareidentifiedduringastudysession,abriefsuicidescreeningassessment(e.g.,Self-InjuriousBehaviorThoughtsandBehaviorInterview(SIBTI)maybeconducted(Appendix7).Ifthereisanimmediateconcernforsafety,theparticipantwillbedirectedtogotothenearestERorcall911/localbehavioralhealthemergencyresponders.Thestudyclinicianwillbealertedandtriagesafetyriskasperthestudysafetyprotocol.Thestudyclinicianwillcontacttheparticipantandemergencycontactasneeded,provideresources,anddeterminewhetheradditionalstepsarenecessary.SymptomdeteriorationwillbedefinedasaPHQ-8score≥15anda≥5-pointincreasefrombaselineoraPHQ-8score≥20attwoconsecutivetimepoints.Ifadeteriorationeventoccurs,analertwillbesenttothestudyteam.Freeformtextenteredinthemobileapp,PSCassessments,anddeteriorationalertswillbereviewedbystudystaffdaily.Anycorrespondencefromastudyparticipantwillalsobereviewed.Ifasafetyconcernisidentified(includingendorsementsoforthoughtsofself-harm,harmingothers,orothersareharmingthem),astudyteammemberwillnotifyastudyclinician.Thecontactedstudyclinicianwillreviewalldeteriorationeventsandconcerningfreeformtextandreachouttoparticipantsandemergencycontactsifindicated,asperthestudysafetyprotocol.TheMedicalExpertclinicianwilldeterminetheoutcomeofadverseeventsandunanticipatedadversedeviceeffectsinconsultationwiththeindependentexternalclinician.Dataaboutindividualsafetyconcerns,AEs,ADEs,andoutcomesofclinicalreachoutmaybesecurelysharedwithparticipants’healthcareproviderorreferringhealthcaresystemuponwrittenauthorizationbytheparticipantand/orlegalguardianaspartoftheinformedconsentprocess.Keywordsorphrasesthatmayindicatesuicidality,self-harm,orharmtootherswilltriggeranautomatedpopupwithinthemobileappdirectingtheparticipanttocontactemergencyresourcesiftheirsafetyisatrisk.Emergencycontactinformationwillbekeptonfileforallparticipantsandparticipants’physicallocationandphonenumberwillbeobtained/confirmedtoallowforeffectivefollowupiftheneedarises.MedicalExpert:AqualifiedandexperiencedlicensedclinicianwillserveastheMedicalExpert.TheMedicalExpertwillreviewallmental-healthrelatedseriousAEandallADEsatthetimetheyarereported.TheMedicalExpertmayrequestameetingoftheDSMBtoreviewsafetydata.Ataminimum,theMedicalExpertwillreviewtheoutcomesofseriousAEsorADEsandthecausalrelationshipoftheAEstotheinvestigationaldevice.IfnoseriousAEsorADEspromptreviewatanearliertimepoint,theDSMBwillreviewAEsandADEsattheregularlyscheduledbiannualmeetings.TheMedicalExpertwillalsoconsultwithanindependentexternalcliniciantoverifysafetyclassifications.FollowinganinitialclassificationofthesafetyeventasanAEorADEbytheMedicalExpert,theindependentexternalclinicianwillreviewthesafetyeventandmakeaseparatedeterminationoftheclassification.Whendiscrepanciesbetweenthetwopartiesoccur,theclassificationmadebytheindependentexternalclinicianwillbemaintained.Thestudycliniciansarelicensedhealthcareprovidersandhaveexperienceintheassessmentofmoodandanxietysymptoms,directingthetreatmentofsuchsymptoms,andaddressingpossibleadversereactionsduringclinicaltrials.TheMedicalExpertwillassessthebenefitsandrisksoftheprotocolonanongoingbasisandwillbeavailabletothestudyteamforquestionsregardinginclusion/exclusioncriteria,protocolconduct,andsafety.TheMedicalExpertwillreviewandevaluateinformationrelevanttothesafetyofthisstudybeforetheimplementationoftheprotocolandwillrecommendalterationstothestudydesignbasedonreviewofsubjectsafetytrends.
LimbixHealthInc./1.0417Studypersonnelwillreviewalldatacollectionmaterialsonanongoingbasisfordatacompletenessandaccuracyaswellasprotocoladherence.ProtocoldeviationsandviolationswillbereportedinaccordancewithIRBandFDAguidelines.Inthisstudy,aprotocolviolationincludesbutisnotlimitedtorandomizationofanineligibleparticipantandfailuretoobtaininformedconsent/assent.AprotocoldeviationincludesbutisnotlimitedtominordeviationsfromprotocolthatdonotimpactsafetyorefficacyandfailuretokeepIRBapprovaluptodate.AformalDataandSafetyMonitoringBoard(DSMB)willbeassembledinaccordancewithNIHandNIMHcriteriatoensurethatthesafetyofstudysubjectsisprotectedandthatthescientificgoalsofthestudyarebeingmet.TheteamassembledfortheDSMBwillhaverelevantandcomplementaryexpertiseinadolescentpsychiatry,clinicaltrialdesign,digitalhealth,andstatistics.Specifically,themembersoftheDSMBwillincludeachildpsychiatristwithexpertiseindepressionandrelateddisorders,abiostatisticianwithexpertiseinclinicaltrialdesignandanalysis,andanexpertindigitalhealth.Importantly,noneoftheseindividualswillbeinvolvedinanyothercapacitywiththisstudyorhaveanypotentialconflictsofinterestinstudy-relatedoutcomes.Additionally,anindependentunblinded,non-votingstatisticianwillreviewthevalidityofdatasummarizedinreportsprovidedtotheDSMBandserveasaconsultantduringmeetings.TheDSMBwillmeet(e.g.teleconference)priortothestartofinterventiontoreviewandproviderecommendationsregardingtheresearchprotocol,informedconsent/assentdocuments,andplansfordatasafetyandmonitoring.SubjectrecruitmentwillbeinitiatedafterreviewofthestudyprotocolbytheDSMB.TheDSMBwillthenmeetonabiannualbasisortwiceduringthestudydurationtoassessdataqualityandtimeliness,participantrecruitment,accrualandretention,participantriskversusbenefit,anybreachesofconfidentiality,aswellastheethicsofthistrial.DetailedinformationwillbeprovidedtotheDSMBpriortoeachofthescheduledmeetings.Thisreportwillincludearangeofinformationonstudyprocedures,measures,familyresponses,methodology,andacceptabilityoftheinterventionandmeasures,aswellasAEs,ADEs,andSAEsexperiencedbystudyparticipants.DataonstudyprogressandprotocolintegritywillbeprovidedtotheDSMBtoensurethatthestudyismovingforwardasplanned.TheDSMBChairpersonmayconveneadditionalmeetingswhendeemednecessary.Within2weeksofmeeting,theDSMBwillprovideawrittenreportoftheirrecommendationtothestudyPIsincludinganymodificationsandrecommendations.TheDSMBwillalsomakerecommendationsatanytimetothesponsor(Limbix),theNIMH(asdeemednecessary),andthestudyPIsconcerningcontinuation,termination,orothermodificationsofthetrialbasedontheobservedbeneficialoradverseeffectsofthetrial.Anyrecommendedchangesoradjustmentsaboutthestudywillbeconsidered.Ifitisdeterminedthattherecommendationscannotbefollowed,thesponsorandstudyPIswillprovideanexplanationofwhytheycannotbefollowedtotheDSMBandtheNIMH.TheIRBwillreceiveablindedsummaryreportofsafetyfindingsonanannualbasisfromthestudyPIs.Thisdataandsafetyreviewaswellasanassessmentofprotocolcomplianceanddataqualitywillfacilitatetheearlydetectionofsafetysignalsandwillmaximizethelikelihoodofcontinuedappropriatenessoftheresearchandprotectionofhumansubjects.ThereviewwillalsoensurethatparticipantswhoexperienceAEsareprovidedwithproperand,ifnecessary,ongoingattention.Anyrecommendationstoimproveparticipantsafety,protocoladherence,ordataqualitywillalsobeincluded.ThestudyPIswillalsoensuresubjectprivacyandresearchdataconfidentiality.AstatisticalpenaltywillnotbeassessedfortheongoingunblindedreviewofsafetybytheDSMB.Unblindeddatawillnotbereleasedtothestudyinvestigatorsunlessnecessaryforsafetyreasons.StudyPIswillreportUADEstotheDSMBchairwithin10businessdaysofbeingnotified.ReportedinformationforeachUADEwillincludedetailedinformationabouttheeventtimeline,thesubject’smedicalhistoryandcurrentconditions,andotherrelevantdata.FurtherdetailsaboutDSMBprocessesandresponsibilitiesarefoundintheDSMBCharter.
LimbixHealthInc./1.04185.DataStorageandConfidentialityEthicalguidelinesforclinicalresearchwillbefollowed.Allinformationobtainedwillbekeptstrictlyconfidentialexceptasrequiredbylawandasotherwiseindicatedinthisprotocolandinformedconsentforms.Wewillcomplywithallmandatedreportingrules.Allresearchersmustdemonstratethroughtrainingandtestingup-to-dateunderstandingofandcommitmenttofollowalltheguidelinesandrulesrelatedtoHIPAA,humansubjectsresearch,andgoodclinicalpracticethatapplytothisresearch.Specialcarewillbetakentopreventunauthorizedaccesstodatafiles.Limbix-ownedcomputersonwhichdatafileswillbeaccessedwillhavepassword-protection.AllstudyparticipantswillbeassignedparticipantIDnumbersuponenrollmentinthestudyandallsubsequentdataprocessingwillbecompletedbyreferencetothesenumbers.ThefilelinkingparticipantIDnumbertopersonalidentifyinginformationwillbestoredinasecure,HIPAAcompliantdatabase.CasereportformswillbestoredonGoogleDrivewithabusinessagreementinplaceprotectingthosefiles.Onlyresearchstaffwhorequireaccessforstudy-relatedactivitieshavepermissionstoviewand/oreditthesefiles.Effortswillbetakentoensurethatinformationobtainedfromhealthcaresystemsorprovidersthatcontainspersonalidentifyinginformation(suchasthenamesofreferredstudyparticipants)willbereceivedthroughsecurechannels(e.g.,secureemail)andstoredinortransferredtoasecure,HIPAAcompliantdatabase.SignedelectronicconsentformswillbestoredthroughPart11compliantservices.Thedatageneratedbythemobileclientorwebportal(usedforbaselineandpost-interventionassessmentsforparticipantsandlegalguardians)willbestoredinanAptiblePostgreSQLdatabase,whichisbackedupdailytogeographicallyseparateregionsandencryptedatrest.Afterthestudy,thedatawillcontinuetobestoredinsaiddatabase.Intheeventthatweneedtodecommissionthedatabase,wewillmovethedatatocoldstorageineitherGoogleCloudPlatformorAmazonWebServices(AWS)fortheremaininglengthoftimerequiredtocomplywithGCPandwillconfigurethosebucketstobeencryptedatrestaswell.AnanonymizedcopyofaportionofthestudydatawillbesynceddailytoGoogleCloudPlatformforeasieranalysis.Thiscopyofthedatawillhavesensitivefieldssuchasemail,phonenumber,andfirstnameremovedandstillrequireavalidLimbixemployeeloginforaccess.AccesstothedatabaserequiresSSHlogintoAptibleephemeralcontainersthatgeneratelogseverytimeanemployeelogsin.AccountsonAptiblearelimitedonaneedbasisandemployeesareassignedtorolesbasedonthelevelofaccesstheyneedtothesystem.TheroleswithaccesstothedatabaseareAccountOwnersandEnclaveOwnersonly.TherewillbearesearcherportalwhereLimbixstaffcanviewaggregateandindividualparticipantdataofaccountsthatareenrolledinthestudy.Accountsontheresearcherportalhaveaccesstostudydatalimitedbyroles.TheroleswithaccesstostudydataareSystemAdmin,StudyAdmin(PIs),StudyOperator,andRead-only.Allcontentontheresearcherportalwillrequirevalidlogincredentialswithpasswordprotection.Datageneratedbythemobileclientorwebportalwillalsobevisiblethroughanadminportal.Accountsontheadminportalwillbelimitedtoemployeesthatneedaccessinordertorunandmaintaintechnicalinfrastructure.Allaccesstotheadminportalwillrequirevalidlogincredentialswithpasswordaswellasaone-timeMFApassword.Anonymoususagedata(suchasbuttonclicksandscreennavigation)generatedbytheSparkRxmobileclientwillbeaggregatedusingGoogleAnalytics.AllaccesstothisdatawillrequireavalidLimbixemployeeloginforaccess.Themobileapplicationwillalsorequirevalidlogincredentialswithpasswordprotectiontoaccessindividualaccountinformation.Ifthemobileappdoesnotcommunicatewiththeserverfor30days,theuserwillbesignedoutoftheiraccountautomaticallyandhavetore-logintoaccesstheirdatainthemobileapplication.Afterparticipantshavecompletedstudyparticipation,theywillbemarkedascompletedbyaresearchstaffmemberviatheresearcherportalandaccesstothemobileapplicationwillberestricted.
LimbixHealthInc./1.0419Onlydesignatedstudystaffwilldirectlycontactstudyparticipantsviaphoneoremailperthestudyprotocoltoanswerstudy-relatedquestions.Textandemailcommunicationisencryptedintransitbutunencryptedwhenbeingsentorreceived.Otherstaffmayinteractwithparticipantstotroubleshootsoftwareissuesthatmayarise.Studycliniciansmaycontactparticipantsand/orlegalguardiansifsafetyconcernsarise,includingworseningmood,inordertomitigaterisks.Communicationswillrecommendthatparticipantscompleteresearch-relatedactivitiesincludingthevirtualconsentprocessinaprivatelocation.Theresearchcoordinatorwillconductallresearch-relatedactivitiesinaprivateroomwhereindividualsbeyondtheresearchinvestigatorsandstaffcannotoverheartheconversation.Participantsareexpectedtocompletetheself-guidedSparkRxprogramatalocationoftheirchoice.Nodatawithsubjectidentifierswillbereleased,unlessauthorizedbystudyparticipantsandlegalguardians,andalldataobtainedwillbestoredandmaintainedinasecuremanner.Allpublicationsorreportsofdatawillbeanonymousinrelationtosubjectidentification.Protectedhealthinformationwillbedisclosedtohealthcareprovidersorreferringhealthcaresystemsonlyuponwrittenauthorizationoftheparticipantand/orlegalguardianaspartoftheinformedconsentprocess.DataUseAgreementswillbeinplacebeforeprotectedhealthinformationissharedwithreferringhealthcaresystems.DatawillbestoredinaconfidentialmanneraftertheresearchiscompletedinaccordancewithGCP.ThePIswillretainresponsibilityforensuringthatdataaremaintainedinasecuremanner.De-identifieddataoralimiteddatasetmaybesharedforfutureresearchbyLimbixafteraDataUseAgreementissigned,whereappropriate.6.TransitionfromResearchParticipationN/A7.Risk/BenefitAssessment7.1RiskCategoryMinimalrisk7.2PotentialRiskPsychologicalrisks:Somepersonalquestionsaboutlifeexperiencesormoodmaybringupuncomfortablefeelings.Lossofconfidentiality:Asthisstudyinvolvestheuseofidentifiable,personalinformation,thereisachancethatalossofconfidentialitywilloccurthoughstepstomitigatethisriskhavebeentakenasdescribedbelow.7.3ProtectionAgainstRiskTominimizepsychologicalrisks,participantswillbeinstructedthattheycanchoosenottoansweranyquestioninanyassessment,andcandiscontinuetheirparticipationatanytime.BecausebaselinePHQ-8scoreandcurrentantidepressantmedicationusearerequiredforstudyrandomization,participantswillbeinformedthatiftheychoosenottorespondtothesequestions,theywillnotbeabletocontinuetheirparticipationinthestudy.Inaddition,becausetheSparkRxmobileappprogressesinalinearfashion,questionsinthemobileprogrammustbeansweredtoprogresstothenexttask.Duringconsent,participantswillbeinformedthattheymaydiscontinuetheirparticipationatanytime.Patientresponsestoassessmentscompletedweeklywillbemonitoredaswellasfreeresponseanswerstoquestionsdeliveredviathemobileapp.Thiswillenabledetectionofdeteriorationinclinicalstatus.Ifsuchdeteriorationoccurs,researchstaffwillimmediatelycontactthePI/studyclinician/MedicalExpert.ParticipationwillbeterminatedifclinicalevidenceindicatesthatcontinuingwouldnotbeinthebestinterestofthesubjectasdeterminedbytheMedicalExpertinconsultationwithastudyclinician.ParticipationwillalsobeterminatediftheMedicalExpertdeterminesthatthesubject’s
LimbixHealthInc./1.0420safetycannotbeadequatelymonitoredand/orcircumstanceswouldpreventthesafetyprotocolfrombeingimplemented(e.g.,participant’slocationcannotbeconfirmedtobewithintheU.S.,healthcareproviderindicatesthatparticipantisnottheirpatientandalternativeproviderinformationcannotbeobtainedinatimelyfashion).Weeklysymptomreportingwillalsohelptheresearchteamtoidentifyanypsychologicalorphysicalhealthconsequencesofstudyparticipationand,inconsultationwithstudycliniciansandtheMedicalExpert,determinethebestwaytomitigatefurtherriskstoparticipanthealth.Nomedicationswillbewithheld;however,participantswillbeaskedtoreportchangestomentalhealth-relatedtreatmentwhileparticipatingintheresearchstudy.Tominimizeriskstoprivacyand/orconfidentiality,onlypersonnelwithtraininginprotectingprivateinformationabouthumansubjectswillhaveaccesstostudydata.Specialcarewillbetakentopreventunauthorizedaccesstodatafiles.Computersonwhichdatafileswillbeaccessedwillhavepassword-protectedaccess.Allstudyparticipantswillbeassignedcodenumbersonentrytothestudyandallsubsequentdataprocessingwillbecompletedbyreferencetothesenumbers.Specialcarewillbetakentopreventunauthorizedaccesstothedatabaseorcasereportformsconnectingparticipantidentitytosubjectnumbers.Allpublicationsorreportsofdatawillbeanonymousinrelationtosubjectidentification.Protectedhealthinformationwillbedisclosedtootherprofessionalstreatingtheparticipantonlyuponwrittenauthorizationoftheparticipant(orlegalguardian).PIswillretainresponsibilityforensuringthatfilesaremaintainedinasecuremannerduringandafterstudy.Studystaffwillensurethatnoindividualsoutsidetheauthorizedteamcanoverhearconversationsduringthevirtualsessions.Participantsinthestudywillbeexpectedtocompletemobileinterventionsatalocationoftheirowndiscretionwithrespecttoprivacyandconfidentiality.Althougheveryreasonableefforthasbeentaken,confidentialityduringInternetandphone-basedcommunicationprocedurescannotbeguaranteedanditispossiblethatadditionalinformationbeyondthatcollectedforresearchpurposesmaybecapturedandusedbyothersnotassociatedwiththisstudy.AnydatasharedinthefuturewillbestrippedofallidentifyinginformationandprotectedhealthinformationoralimiteddatasetmaybesharedwithaDataUseAgreement,whenapplicable.7.4PotentialBenefitstotheSubjectsNodirectbenefitscanbeguaranteedbyparticipatinginthisresearchprotocol.Asparticipantsintheinterventionarmwillreceiveamobileprogramdesignedtobetherapeutic,theymayexperiencedirectbenefitsfromparticipationintermsofreducedsymptomsofdepression,aswellaspotentialreductionsincomorbidanxietysymptoms,andimprovementsinmood,and/orfunctionaloutcomes.Participantsmayalsodirectlybenefitfromparticipatingintheproposedresearchbecauseoftheknowledgeobtained.Assessmentsandprocedurescompletedduringthestudymayprovideparticipantswithanopportunitytoreflectontheirthoughts,feelings,andbehaviorswhichmaybevaluableinhelpingindividualsbetterunderstandtheirownemotionalfunctioning.Thesebenefitsoutweightheminimalrisksassociatedwiththistrial.Participantswillhavetheopportunitytoprovidefeedbackabouttheinterventiontohelpimprovetheprogramforfutureusers.Thisabilitytohelpothersmayalsohavetherapeuticbenefitsforparticipants.7.5AlternativestoParticipationProspectiveparticipantswhodeclinetoenrollinthisstudyarefreetoconsideralternatives,includingseeking
LimbixHealthInc./1.0421treatment.Standardofcaretreatmentforadolescentdepressiontypicallyincludespsychotherapywithorwithoutantidepressants,dependingonclinicallydeterminedvariables.Mentalhealthresourceswillbesharedwithpotentialparticipantswhodeclinetoparticipateinthisstudybutaretreatment-seeking.However,alternativetreatmentsarenotpromisedorguaranteed.Participantsmayalsoparticipateinanotherresearchstudyornotseekanytreatment.8.SubjectIdentification,RecruitmentandConsent/Assent8.1MethodofSubjectIdentificationandRecruitmentParticipantswillberecruitedthroughcommunitysamplingandprovider-orhealthcaresystem-facilitatedcommunityrecruitment.Contractresearchorganizations(CROs)andotherreferralbasedrecruitmentcompaniesmaybeusedtocontactpotentialparticipants,providers,andhealthcaresystems.8.2ProcessofConsentPriortoparticipation,electronicconsentwillbeobtainedforallparticipantsover18.Forparticipantsunder18,electronicassentwillbeobtained,andelectronicconsentwillbeobtainedfromalegalguardianunlesstheminorislegallyemancipatedorfinanciallyindependentinaccordancewithCAstateregulationsandregulationsofthestateinwhichtheminorresides.Anytrainedmemberoftheresearchteamwillbeauthorizedtoobtaininformedconsent/assent.Forconsentprocessesthatarecompletedvirtuallyviavideoconferencing,toensureparticipantprivacy,theresearchstaffmemberconductingtheconsentprocesswillensurethatnooneoutsideoftheresearchteamcanoverheartheconsentprocessfromtheirendandwillrecommendthatthepotentialparticipantjointhevideoconferencefromaprivatelocation.Theresearcherwillprovideanexplanationofthestudyandtheconsentform(liveorvideo-recorded),taketimetoansweranyquestions,providetimefordecision-making,andrequestanelectronicsignature.Participants(andlegalguardians,whereapplicable)willbeinformedthattheirparticipationisvoluntary,theyarefreetodiscontinueparticipationatanytime,andallinformationwillbekeptconfidential,except:1)legally-mandatedexceptionstoconfidentiality,e.g.,ifaparticipantreportsthattheyareatriskofharmingthemselvesorsomeoneelse,orthatsomeoneisharmingthem,and2)legalguardiansofminorparticipantswillbeinformedwhenastudycliniciandeterminesthatclinicalcontactwiththeparticipantorlegalguardianiswarranted.Forexample,legalguardianswillbecontactedifaparticipantunder18yearsofageexhibitspotentialworseningofpsychologicalsymptomsasindicatedinappfreeformtextorweeklycheck-inresponses.Participantswillbetoldthatfreeformtextentriesinthemobileappduringthestudywillbereviewed,butnotinrealtime.Itwillbeclearlycommunicatedtoallparticipantsthatthisinterventionisnotintendedtopreventsuicideattemptsorself-harmbehaviorsandthattheinterventionisnotforemergencycare.Allpotentialrisksordiscomfortswillbeexplicitlylistedandexplained.Participantswillalsobeaskedtoindicatewhetherornotthey’dbewillingtobecontactedregardingfutureresearchopportunities.Participantswillbeaskedifde-identifiedwrittenorspokenstatementstheyprovideduringthestudycanbeusedinanymarketingmaterialsorpublicationsandcanoptoutfromallowinganyde-identifiedstatementstheyprovidetobeshared.Consentforms,aswellasverbalpresentations(videoconferenceandvideo),willadditionallyemphasize:1)Thisisaresearchstudytestinganinvestigationalmedicaldeviceintendedasatreatmentforsymptomsofdepression;2)Possible(minimal)risksandbenefitsofparticipation;3)Participantscanelectnottorespondtoanyquestion(s)theyarenotcomfortableanswering,withtheexceptionofthebaselineassessmentsrequiredforstudyenrollment;4)Participantscanchoosetoendtheirparticipationatanytimeforanyreason;5)Allinformationwillbekeptconfidentialwiththeexceptionofcertaininformationthatmustbereportedforlegalorethicalreasonsincludingsuspectedchildabuseorneglect,suspectedelderabuseorneglect,or
LimbixHealthInc./1.0422intenttoharmoneselforothers.Theconsentprocesswillbeconsideredcompleteonlyiftheparticipant(andlegalguardian,ifapplicable)demonstratescomprehensionofallstudyprocedures.Thiswillbedeterminedthroughcomprehensionquestionsandconversationwithstudystaff.Afterallquestionsconcerningthestudyhavebeenfullyansweredbystudystaff,aPart11compliant,electronicsignaturewillbeobtainedfromtheparticipanttodocumentconsent.Documentationoftheassentofaminorwillalsobeobtained.Participants(orlegalguardians)willberequiredtodisplayavalidformofidentificationtoverifyidentity.Participantswillbeprovidedwithalinktoaccessanddownloadacopyofthesignedconsent/assentformatanytime.Signedelectronicconsent/assentformswillbestoredinaHIPAAcompliantserver.Ifaminorwillbecomeoflegalconsentingageduringtheirparticipationinthestudy,theywillberequiredtoconsentatthattimetocontinuingtheirparticipation.8.3SubjectCapacityThestudywillnotenrollparticipantswhoareunabletoprovideconsentorassent(ifpotentialparticipantsareunder18).Discussionsbetweenpotentialparticipantsandresearchstaffmembersduringthevideoconferencingsessionwilldiscloseanyobviousadditionalcomprehensionproblemsorphysicallimitationsthatwouldprohibitparticipation.Cognitiveandphysicallimitationsthatwouldprecludeparticipationareincludedaspartofstudyeligibilitycriteria.8.4SubjectComprehensionAllparticipantswillviewavideorecordedexplanation,scriptedata5thgradereadinglevel,ofthepurpose,procedures,andpotentialrisksofthestudyandoftheirrightsasresearchparticipants.Participants(andlegalguardians)willbegivenampletimeandopportunitytocarefullyreviewtheconsent/assentformandaskquestionsregardingthisstudytostudystaff,family,friends,and/ordoctorspriortosigning.Understandingwillbeconfirmedbyspecificquestionspresentedtopotentialparticipants(andlegalguardians)duringtheconsentingprocess.8.5DebriefingProceduresNoinformationwillbepurposefullywithheldfromparticipants.8.6ConsentFormsThefollowinginformedconsentformsarebeingsubmittedwiththisprotocol:1.InformedConsent8.7DocumentationofConsentAPart11compliant,electronicsignaturewillbeobtainedfromtheparticipant(orlegalguardian)todocumentconsent.Documentationoftheassentofaminorwillalsobeobtained.Participantswillbeprovidedwithalinktoaccessanddownloadacopyofthesignedconsentformatanytime.Signedelectronicconsent/assentformswillbestoredthroughPart11compliantservices.8.8CoststotheSubjectParticipantsareexpectedtoprovidepaymentforclinicalcarethatisnotpartofthisresearchprotocol(e.g.,hospitalizationcosts)throughstandardhealthcarepaymentprocedures.Participantswillhavenocostsassociatedwithresearchparticipation,beyondthoseassociatedwithphoneandinternetusage.Limbixwillpayforallproceduresassociatedwiththestudyornecessarystudy-relatedfollow-up.8.9PaymentforParticipationParticipantswillbecompensatedforcompletingassessments,includingbaseline,in-app,post-intervention,
LimbixHealthInc./1.0423and1-monthfollow-upquestionnaires.Thepaymentamountwillbedeterminedbasedonwhethertheycomplete(“fullcompliance”),partiallycomplete(“partialcompliance”),ordonotcomplete(“nocompliance”)studyquestionnairesateachtimepoint.CompensationforparticipantsrandomizedtotheSparkRxinterventionwillnotbecontingentoncompletionofmobileappmodulesduringtheinterventionperiod.Caregiverswhoattendthevideoconferencingsessionwiththeirchildwillbecompensatedfortheirtime.Participantsandcaregiverswillbepaidintheformofelectronicgiftcards.
LimbixHealthInc./1.0424REFERENCES1Patton,G.C.etal.Ourfuture:aLancetcommissiononadolescenthealthandwellbeing.Lancet387,2423-2478,(2016).2Keyes,K.M.,Gary,D.,O'Malley,P.M.,Hamilton,A.&Schulenberg,J.RecentincreasesindepressivesymptomsamongUSadolescents:trendsfrom1991to2018.SocPsychiatryPsychiatrEpidemiol54,987-996,(2019).3Eaton,D.K.etal.Youthriskbehaviorsurveillance-UnitedStates,2009.MMWRSurveillSumm59,1-142,(2010).4Racine,N.,McArthur,B.A.,Cooke,J.E.,Eirich,R.,Zhu,J.,&Madigan,S.(2021).GlobalprevalenceofdepressiveandanxietysymptomsinchildrenandadolescentsduringCOVID-19:ameta-analysis.JAMApediatrics,175(11),1142-1150.5Mojtabai,R.,Olfson,M.&Han,B.NationalTrendsinthePrevalenceandTreatmentofDepressioninAdolescentsandYoungAdults.Pediatrics138,e20161878,(2016).6Twenge,J.M.,Cooper,A.B.,Joiner,T.E.,Duffy,M.E.&Binau,S.G.Age,period,andcohorttrendsinmooddisorderindicatorsandsuicide-relatedoutcomesinanationallyrepresentativedataset,2005–2017.Journalofabnormalpsychology,(2019).7Twenge,J.M.,Joiner,T.E.,Rogers,M.L.&Martin,G.N.IncreasesinDepressiveSymptoms,Suicide-RelatedOutcomes,andSuicideRatesAmongU.S.AdolescentsAfter2010andLinkstoIncreasedNewMediaScreenTime.ClinicalPsychologicalScience6,3-17,(2017).8Copeland,W.E.,Shanahan,L.,Costello,E.J.&Angold,A.Childhoodandadolescentpsychiatricdisordersaspredictorsofyoungadultdisorders.Archivesofgeneralpsychiatry66,764-772,(2009).9Esposito,C.L.&Clum,G.A.Psychiatricsymptomsandtheirrelationshiptosuicidalideationinahigh-riskadolescentcommunitysample.JournaloftheAmericanAcademyofChild&AdolescentPsychiatry41,44-51,(2002).10Keenan-Miller,D.,Hammen,C.L.&Brennan,P.A.Healthoutcomesrelatedtoearlyadolescentdepression.JournalofAdolescentHealth41,256-262,(2007).11Marmorstein,N.R.Longitudinalassociationsbetweenalcoholproblemsanddepressivesymptoms:earlyadolescencethroughearlyadulthood.Alcoholism:ClinicalandExperimentalResearch33,49-59,(2009).12McCarty,C.A.etal.Developmentalconsistencyinassociationsbetweendepressivesymptomsandalcoholuseinearlyadolescence.Journalofstudiesonalcoholanddrugs73,444-453,(2012).13Ahmedani,B.K.,Peterson,E.L.,Wells,K.E.&Williams,L.K.Examiningtherelationshipbetweendepressionandasthmaexacerbationsinaprospectivefollow-upstudy.Psychosomaticmedicine75,305,(2013).14Rofey,D.L.etal.Alongitudinalstudyofchildhooddepressionandanxietyinrelationtoweightgain.Childpsychiatryandhumandevelopment40,517-526,(2009).15Thapar,A.,Collishaw,S.,Pine,D.S.&Thapar,A.K.Depressioninadolescence.Lancet(London,England)379,1056-1067,(2012).16Weissman,M.M.etal.Depressedadolescentsgrownup.Jama281,1707-1713,(1999).17Fergusson,D.M.,Horwood,L.J.,Ridder,E.M.&Beautrais,A.L.Subthresholddepressioninadolescenceandmentalhealthoutcomesinadulthood.Archivesofgeneralpsychiatry62,66-72,(2005).18Kim-Cohen,J.etal.Priorjuvenilediagnosesinadultswithmentaldisorder:developmentalfollow-backofaprospective-longitudinalcohort.Archivesofgeneralpsychiatry60,709-717,(2003).19Bardone,A.M.etal.Adultphysicalhealthoutcomesofadolescentgirlswithconductdisorder,depression,andanxiety.JournaloftheAmericanAcademyofChild&AdolescentPsychiatry37,594-601,(1998).20Kessler,R.C.Thecostsofdepression.PsychiatricClinics35,1-14,(2012).21Lynch,F.L.&Clarke,G.N.Estimatingtheeconomicburdenofdepressioninchildrenandadolescents.Americanjournalofpreventivemedicine31,143-151,(2006).
LimbixHealthInc./1.042522Korczak,D.J.&Goldstein,B.I.ChildhoodOnsetMajorDepressiveDisorder:CourseofIllnessandPsychiatricComorbidityinaCommunitySample.TheJournalofPediatrics155,118-123,(2009).23Birmaher,B.,Arbelaez,C.&Brent,D.Vol.11619-638(ElsevierScience,Netherlands,2002).24Wisdom,J.P.,Clarke,G.N.&Green,C.A.Whatteenswant:barrierstoseekingcarefordepression.AdmPolicyMentHealth33,133-145,(2006).25Birmaher,B.etal.ChildhoodandAdolescentDepression:AReviewofthePast10Years.PartI.JournaloftheAmericanAcademyofChild&AdolescentPsychiatry35,1427-1439,(1996).26Galea,S.,Merchant,R.M.&Lurie,N.TheMentalHealthConsequencesofCOVID-19andPhysicalDistancing:TheNeedforPreventionandEarlyIntervention.JAMAInternalMedicine,(2020).27Xiang,Y.-T.etal.Timelymentalhealthcareforthe2019novelcoronavirusoutbreakisurgentlyneeded.TheLancetPsychiatry7,228-229,(2020).28Brooks,S.K.etal.Thepsychologicalimpactofquarantineandhowtoreduceit:rapidreviewoftheevidence.TheLancet395,912-920,(2020).29Federici,S.,Bracalenti,M.,Meloni,F.&Luciano,J.V.WorldHealthOrganizationdisabilityassessmentschedule2.0:Aninternationalsystematicreview.Disabilityandrehabilitation39,2347-2380,(2017).30AguirreVelasco,A.,Cruz,I.S.S.,Billings,J.,Jimenez,M.&Rowe,S.Whatarethebarriers,facilitatorsandinterventionstargetinghelp-seekingbehavioursforcommonmentalhealthproblemsinadolescents?Asystematicreview.BMCPsychiatry20,293(2020)31Radez,J.etal.Whydochildrenandadolescents(not)seekandaccessprofessionalhelpfortheirmentalhealthproblems?Asystematicreviewofquantitativeandqualitativestudies.Eur.ChildAdolesc.Psychiatry30,183–211(2021).32O’Dea,B.,Calear,A.L.&Perry,Y.Ise-healththeanswertogapsinadolescentmentalhealthserviceprovision?Currentopinioninpsychiatry28,336-342,(2015).33Sheppard,R.,Deane,F.P.&Ciarrochi,J.Unmetneedforprofessionalmentalhealthcareamongadolescentswithhighpsychologicaldistress.Australian&NewZealandJournalofPsychiatry52,59-67,(2018).34Cheetham,A.etal.StigmatisingAttitudesTowardsDepressionandAlcoholMisuseinYoungPeople:RelationshipswithHelp-SeekingIntentionsandBehavior.AdolescentPsychiatry9,24-32,(2019).35SupplyandDemandProjectionsoftheNursingWorkforce:2014-2030.22.36Andrilla,C.H.A.,Patterson,D.G.,Garberson,L.A.,Coulthard,C.&Larson,E.H.Geographicvariationinthesupplyofselectedbehavioralhealthproviders.Americanjournalofpreventivemedicine54,S199-S207,(2018).37Cunningham,P.J.BeyondParity:PrimaryCarePhysicians'PerspectivesOnAccessToMentalHealthCare:MorePCPshavetroubleobtainingmentalhealthservicesfortheirpatientsthanhaveproblemsgettingotherspecialtyservices.Healthaffairs28,w490-w501,(2009).38Thomas,C.R.&HolzerIii,C.E.Thecontinuingshortageofchildandadolescentpsychiatrists.JournaloftheAmericanAcademyofChild&AdolescentPsychiatry45,1023-1031,(2006).39Williams,M.E.,Latta,J.&Conversano,P.Eliminatingthewaitformentalhealthservices.JBehavHealthServRes35,107-114,(2008).40Kowalewski,K.,McLennan,J.D.&McGrath,P.J.ApreliminaryinvestigationofwaittimesforchildandadolescentmentalhealthservicesinCanada.JCanAcadChildAdolescPsychiatry20,112-119,(2011).41Schraeder,K.E.&Reid,G.J.Whywait?Theeffectofwait-timesonsubsequenthelp-seekingamongfamilieslookingforchildren'smentalhealthservices.JAbnormChildPsychol43,553-565,(2015).42Westin,A.M.L.,Barksdale,C.L.&Stephan,S.H.Theeffectofwaitingtimeonyouthengagementtoevidencebasedtreatments.Communitymentalhealthjournal50,221-228,(2014).43Smith,D.H.,Hadorn,D.C.&SteeringCommitteeofTheWesternCanadaWaitingList,P.Liningupforchildren'smentalhealthservices:atoolforprioritizingwaitinglists.JAmAcadChildAdolescPsychiatry41,367-376;discussion376-367,(2002).44Biringer,E.,Sundfør,B.,Davidson,L.,Hartveit,M.&Borg,M.Lifeonawaitinglist:Howdopeopleexperienceandcopewithdelayedaccesstoacommunitymentalhealthcenter?Scandinavian
LimbixHealthInc./1.0426Psychologist2,(2015).45Bose,J.KeySubstanceUseandMentalHealthIndicatorsintheUnitedStates:Resultsfromthe2017NationalSurveyonDrugUseandHealth.124(2017)46Kataoka,S.H.,Zhang,L.&Wells,K.B.UnmetneedformentalhealthcareamongU.S.children:variationbyethnicityandinsurancestatus.AmJPsychiatry159,1548-1555,(2002).47Gunnell,D.etal.SuicideriskandpreventionduringtheCOVID-19pandemic.TheLancetPsychiatry,(2020).48Orben,A.,Tomova,L.&Blakemore,S.-J.Theeffectsofsocialdeprivationonadolescentsocialdevelopmentandmentalhealth.(2020).49Zuckerbrot,R.A.etal.GuidelinesforAdolescentDepressioninPrimaryCare(GLAD-PC):partI.Practicepreparation,identification,assessment,andinitialmanagement.Pediatrics141,e20174081,(2018).50Jureidini,J.N.etal.Efficacyandsafetyofantidepressantsforchildrenandadolescents.Bmj328,879-883,(2004).51Cipriani,A.etal.Comparativeefficacyandtolerabilityofantidepressantsformajordepressivedisorderinchildrenandadolescents:anetworkmeta-analysis.TheLancet388,881-890,(2016).52DeBar,L.L.,Clarke,G.N.,O'Connor,E.&Nichols,G.A.Treatedprevalence,incidence,andpharmacotherapyofchildandadolescentmooddisordersinanHMO.MentalHealthServicesResearch3,73-89,(2001).53Cheung,A.H.,Emslie,G.J.&Mayes,T.L.Reviewoftheefficacyandsafetyofantidepressantsinyouthdepression.JournalofChildPsychologyandPsychiatry46,735-754,(2005).54Whittington,C.J.etal.Selectiveserotoninreuptakeinhibitorsinchildhooddepression:systematicreviewofpublishedversusunpublisheddata.TheLancet363,1341-1345,(2004).55Stafford,A.M.etal.TheNaturalCourseofAdolescentDepressionTreatmentinthePrimaryCareSetting.JournalofPediatricHealthCare34,38-46,(2020).56O’Connor,B.C.etal.Usualcareforadolescentdepressionfromsymptomidentificationthroughtreatmentinitiation.JAMApediatrics170,373-380,(2016).57Powell,A.C.,Chen,M.&Thammachart,C.TheEconomicBenefitsofMobileAppsforMentalHealthandTelepsychiatryServicesWhenUsedbyAdolescents.ChildAdolescPsychiatrClinNAm26,125-133,(2017).58Pennant,M.E.etal.Computerisedtherapiesforanxietyanddepressioninchildrenandyoungpeople:asystematicreviewandmeta-analysis.BehavResTher67,1-18,(2015).59Hollis,C.etal.AnnualResearchReview:Digitalhealthinterventionsforchildrenandyoungpeoplewithmentalhealthproblems–asystematicandmeta-review.JournalofChildPsychologyandPsychiatry58,474-503,(2017).60Irvine.Report:MoreyouthusesmartphonesasroutetoWeb.MidlandReporter-Telegramhttps://www.mrt.com/news/article/Report-More-youth-use-smartphones-as-route-to-Web-7432548.php(2013).61Montague,A.E.,Varcin,K.J.,Simmons,M.B.&Parker,A.G.Puttingtechnologyintoyouthmentalhealthpractice:youngpeople’sperspectives.SageOpen5,2158244015581019,(2015).62Fein,J.A.etal.Feasibilityandeffectsofaweb-basedadolescentpsychiatricassessmentadministeredbyclinicalstaffinthepediatricemergencydepartment.Archivesofpediatrics&adolescentmedicine164,1112-1117,(2010).63Gardner,W.etal.Screening,triage,andreferralofpatientswhoreportsuicidalthoughtduringaprimarycarevisit.Pediatrics125,945-952,(2010).64Bradford,S.&Rickwood,D.Acceptabilityandutilityofanelectronicpsychosocialassessment(myAssessment)toincreaseself-disclosureinyouthmentalhealthcare:aquasi-experimentalstudy.BMCpsychiatry15,305,(2015).65Scott,M.A.etal.School-basedscreeningtoidentifyat-riskstudentsnotalreadyknowntoschoolprofessionals:theColumbiasuicidescreen.AmericanJournalofPublicHealth99,334-339,(2009).66Cho,H.-W.ALongJourneyBacktoNormalLife.OsongPublicHealthandResearchPerspectives11,65,(2020).
LimbixHealthInc./1.042767Torous,J.,Myrick,K.J.,Rauseo-Ricupero,N.&Firth,J.DigitalMentalHealthandCOVID-19:UsingTechnologyTodaytoAcceleratetheCurveonAccessandQualityTomorrow.JMIRmentalhealth7,e18848,(2020).68Liu,S.etal.OnlinementalhealthservicesinChinaduringtheCOVID-19outbreak.TheLancetPsychiatry7,e17-e18,(2020).69Coronavirusdisease(COVID-19)–WorldHealthOrganization.https://www.who.int/emergencies/diseases/novel-coronavirus-2019.70Vibhakar,V.,Allen,L.R.,Gee,B.&Meiser-Stedman,R.Asystematicreviewandmeta-analysisontheprevalenceofdepressioninchildrenandadolescentsafterexposuretotrauma.Journalofaffectivedisorders,(2019).71Burke,A.R.,McCormick,C.M.,Pellis,S.M.&Lukkes,J.L.Impactofadolescentsocialexperiencesonbehaviorandneuralcircuitsimplicatedinmentalillnesses.Neuroscience&BiobehavioralReviews76,280-300,(2017).72Beardslee,W.R.,Gladstone,T.R.G.&O'Connor,E.E.Developmentalriskofdepression:experiencematters.ChildandAdolescentPsychiatricClinics21,261-278,(2012).73Luyten,P.&Fonagy,P.Thestress–reward–mentalizingmodelofdepression:AnintegrativedevelopmentalcascadeapproachtochildandadolescentdepressivedisorderbasedontheResearchDomainCriteria(RDoC)approach.Clinicalpsychologyreview64,87-98,(2018).74Brooks,S.K.etal.Thepsychologicalimpactofquarantineandhowtoreduceit:rapidreviewoftheevidence.TheLancet,(2020).75HenjeBlom,E.etal.Theneuroscienceandcontextofadolescentdepression.ActaPaediatrica105,358-365,(2016).76Compton,S.N.etal.Cognitive-behavioralpsychotherapyforanxietyanddepressivedisordersinchildrenandadolescents:anevidence-basedmedicinereview.JournaloftheAmericanAcademyofChild&AdolescentPsychiatry43,930-959,(2004).77April2001,30.TheNationalCollaboratingCentreforMentalHealth.GuidelinesinPracticehttps://www.guidelinesinpractice.co.uk/mental-health/the-national-collaborating-centre-for-mental-health/300529.article.78Hofmann,S.G.,Asnaani,A.,Vonk,I.J.,Sawyer,A.T.&Fang,A.TheEfficacyofCognitiveBehavioralTherapy:AReviewofMeta-analyses.CognitTherRes36,427-440,(2012).79Yang,L.etal.Efficacyandacceptabilityofcognitivebehavioraltherapyfordepressioninchildren:Asystematicreviewandmeta-analysis.Academicpediatrics17,9-16,(2017).80Hetrick,S.E.,Cox,G.R.,Witt,K.G.,Bir,J.J.&Merry,S.N.Cognitivebehaviouraltherapy(CBT),third‐waveCBTandinterpersonaltherapy(IPT)basedinterventionsforpreventingdepressioninchildrenandadolescents.CochraneDatabaseofSystematicReviews,(2016).81Clarke,G.etal.Cognitivebehavioraltherapyinprimarycareforyouthdecliningantidepressants:arandomizedtrial.Pediatrics137,e20151851,(2016).82Ebert,D.D.etal.InternetandComputer-BasedCognitiveBehavioralTherapyforAnxietyandDepressioninYouth:AMeta-AnalysisofRandomizedControlledOutcomeTrials.PLOSONE10,e0119895,(2015).83Kanter,J.W.etal.Whatisbehavioralactivation?Areviewoftheempiricalliterature.ClinPsycholRev30,608-620,(2010).84Lejuez,C.W.,Hopko,D.R.,Acierno,R.,Daughters,S.B.&Pagoto,S.L.Tenyearrevisionofthebriefbehavioralactivationtreatmentfordepression:revisedtreatmentmanual.BehavModif35,111-161,(2011).85Pass,L.,Lejuez,C.W.&Reynolds,S.BriefBehaviouralActivation(BriefBA)forAdolescentDepression:APilotStudy.BehavCognPsychother46,182-194,(2018).86McCauley,E.etal.TheAdolescentBehavioralActivationProgram:AdaptingBehavioralActivationasaTreatmentforDepressioninAdolescence.JClinChildAdolescPsychol45,291-304,(2016).87Pass,L.,Hodgson,E.,Whitney,H.&Reynolds,S.BriefBehavioralActivationTreatmentforDepressed
LimbixHealthInc./1.0428AdolescentsDeliveredbyNonspecialistClinicians:ACaseIllustration.CognitiveandBehavioralPractice25,208-224,(2018).88Davey,C.G.,Yucel,M.&Allen,N.B.Theemergenceofdepressioninadolescence:developmentoftheprefrontalcortexandtherepresentationofreward.NeurosciBiobehavRev32,1-19,(2008).89Forbes,E.E.etal.Alteredstriatalactivationpredictingreal-worldpositiveaffectinadolescentmajordepressivedisorder.AmJPsychiatry166,64-73,(2009).90Bower,P.,Gilbody,S.,Richards,D.,Fletcher,J.&Sutton,A.Collaborativecarefordepressioninprimarycare.Makingsenseofacomplexintervention:systematicreviewandmeta-regression.DatabaseofAbstractsofReviewsofEffects(DARE):Quality-assessedReviews[Internet](CentreforReviewsandDissemination(UK),2006)91Chu,B.C.,Colognori,D.,Weissman,A.S.&Bannon,K.Vol.16408-419(ElsevierScience,Netherlands,2009).92Jacob,M.,L.Keeley,M.,Ritschel,L.&Craighead,W.E.Behaviouralactivationforthetreatmentoflow-income,AfricanAmericanadolescentswithmajordepressivedisorder:acaseseries.ClinicalPsychology&Psychotherapy20,87-96,(2013).93Ritschel,L.,L.Ramirez,C.,Jones,M.&EdwardCraighead,W.BehavioralActivationforDepressedTeens:APilotStudy.CognitiveandBehavioralPractice18,281-299,(2011).94NationalCollaboratingCentreforMental,H.inDatabaseofAbstractsofReviewsofEffects(DARE):Quality-assessedReviews[Internet](CentreforReviewsandDissemination(UK),2005).95Rooksby,M.,Elouafkaoui,P.,Humphris,G.,Clarkson,J.&Freeman,R.Internet-assisteddeliveryofcognitivebehaviouraltherapy(CBT)forchildhoodanxiety:Systematicreviewandmeta-analysis.JournalofAnxietyDisorders29,83-92,(2015).96Grist,R.,Croker,A.,Denne,M.&Stallard,P.TechnologyDeliveredInterventionsforDepressionandAnxietyinChildrenandAdolescents:ASystematicReviewandMeta-analysis.ClinChildFamPsycholRev22,147-171,(2019).97Oud,M.etal.EffectivenessofCBTforchildrenandadolescentswithdepression:Asystematicreviewandmeta-regressionanalysis.EurPsychiatry57,33-45,(2019).98Webb,C.A.etal.CognitiveversusbehavioralskillsinCBTfordepressedadolescents:Disaggregatingwithin-patientversusbetween-patienteffectsonsymptomchange.JConsultClinPsychol87,484-490,(2019).99Huguet,A.etal.ASystematicReviewofCognitiveBehavioralTherapyandBehavioralActivationAppsforDepression.PLoSOne11,e0154248,(2016).100Kroenke,K.,Strine,T.W.,Spitzer,R.L.,Williams,J.B.,Berry,J.T.,&Mokdad,A.H.(2009).ThePHQ-8asameasureofcurrentdepressioninthegeneralpopulation.Journalofaffectivedisorders,114(1-3),163-173.101Löwe,B.,Unützer,J.,Callahan,C.M.,Perkins,A.J.,&Kroenke,K.(2004).Monitoringdepressiontreatmentoutcomeswiththepatienthealthquestionnaire-9.Medicalcare,1194-1201.102Coley,R.Y.,Boggs,J.M.,Beck,A.,Hartzler,A.L.,&Simon,G.E.(2020).Definingsuccessinmeasurement-basedcarefordepression:acomparisonofcommonmetrics.Psychiatricservices,71(4),312-318.103Spitzer,R.L.,Kroenke,K.,Williams,J.B.,&Löwe,B.(2006).Abriefmeasureforassessinggeneralizedanxietydisorder:theGAD-7.Archivesofinternalmedicine,166(10),1092-1097.104Endicott,J.,Nee,J.,Yang,R.,&Wohlberg,C.(2006).Pediatricqualityoflifeenjoymentandsatisfactionquestionnaire(PQ-LES-Q):reliabilityandvalidity.JournaloftheAmericanAcademyofChild&AdolescentPsychiatry,45(4),401-407.105Kanter,J.W.,Mulick,P.S.,Busch,A.M.,Berlin,K.S.,&Martell,C.R..(2012).BehavioralActivationforDepressionScale(BADS)(LongandShortForm).MeasurementInstrumentDatabasefortheSocialScience.Retrievedfromwww.midss.ie106Sauro,J.(2011,February3).Measuringusabilitywiththesystemusabilityscale(SUS).MeasuringU.RetrievedMay9,2022,fromhttps://measuringu.com/sus/
LimbixHealthInc./1.0429107O’Brien,H.L.,Cairns,P.,&Hall,M.(2018).Apracticalapproachtomeasuringuserengagementwiththerefineduserengagementscale(UES)andnewUESshortform.InternationalJournalofHuman-ComputerStudies,112,28-39.